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Summary 
According to the World Health Organization (WHO) the threat of global antibiotic 
resistance of bacteria is no longer a prediction, but a reality; indeed, it affects every 
region of the world and potentially people of any age. Antibiotic resistant Gram-
negative bacteria are one of the major issues currently affecting global health, mainly 
due to a lack of effective antibiotic therapy for this type of infection. Within this 
context, the EU Commission launched a call in 2013 encouraging the development of 
novel nanotherapeutics to treat bacterial infectious diseases. One of the projects 
selected in this call was the PneumoNP project, a collaborative work funded under the 
FP7-NMP-2013-LARGE-7 call (No. 604434 grant). The aim of the project was to develop 
a therapeutic system for the treatment of lung Gram-negative bacterial infections, 
based on the combination of an antimicrobial peptide (AMP) and a nanocarrier (NC) to 
yield the resulting nanomedicine (or nanosystem, NS), and focusing the attention on 
Klebsiella pneumoniae caused infections for proof of concept experiments. In parallel, 
the project aimed at developing a new nebulization system for the administration of 
aerosols in experimental animals and the validation of a diagnostic kit.  
The consortium as a whole included 11 partners from 6 member states (Spain, 
Germany, Italy, France, The Netherlands and Denmark) coming from different scientific 
and technological disciplines. Two of the partners were devoted to the development of 
novel antimicrobial peptides (AMPs); two of the partners were devoted to the 
preparation of nanocarriers and the development of strategies for the formation of the 
nanosystems; one of the partners was in charge of developing a new nebulizer for the 
administration of the aerosols to rodents and another partner was in charge of 
performing in vivo proof of efficacy studies with selected NSs in relevant animal 
models.  
In this context, The Radiochemistry and Nuclear Imaging Group at CIC biomaGUNE, in 
which this PhD thesis has been carried out, had two major roles: (i) To evaluate the 
novel nebulization system developed within the project; and (ii) to assess the 
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biodistribution and basic pharmacokinetic properties of the nanosystems developed in 
the context of the project using in vivo imaging.  
The work performed in this thesis has been divided in three main parts, which result in 
the three experimental chapters. First, a new tool for the assessment of lung 
ventilation using Positron Emission Tomography (PET) has been developed and 
evaluated in healthy (wild type) animals (rats). Despite this task was not formally 
included in the PneumoNP project description and the results have not been used in 
the context of the PneumoNP project, it is considered as an essential tool for future 
works. Indeed, evaluation of the biodistribution or determination of pharmacokinetic 
properties of new chemical/biological entities after lung administration requires 
previous evidence of unaltered ventilation, which can be assessed efficiently and with 
high sensitivity with the newly developed tool. 
The second part of the PhD thesis focused on the evaluation of the new nebulization 
system and its comparison towards commercially available systems. In this chapter, 
and by using a straightforward methodology to radiolabel the aerosol, the new system 
was evaluated using PET in terms of uniformity of deposition of the aerosol in the 
lungs and the percentage of the aerosol that was actually released in the target organ.  
The last part of this PhD thesis pursued the determination of the residence time in the 
lungs of two novel AMPs after lung administration, both as free peptides and in 
combination with nanocarriers. With that aim, radiolabelling strategies to incorporate 
either positron or gamma emitters into the different species were developed. In 
addition, imaging studies were conducted to determine the residence time in the lungs 
of the labelled AMPs and, eventually, of the nanocarriers. These studies provided 
evidence about the feasibility of nuclear imaging techniques to investigate innovative 
nanomedicines in the preclinical setting, where they can provide information about 
the advantages and limitations of using nanocarriers as drug delivery systems. 
Additionally, essential pharmacokinetic information for proper planning of therapeutic 
experiments could be obtained.  
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Resumen 
La mayoría de los actores y responsables internacionales del sector de la salud pública 
coinciden en que las infecciones provocadas por bacterias Gram-negativas resistentes 
a los antibióticos constituyen una de las mayores amenazas para la salud mundial a día 
de hoy, principalmente debido a la falta de antibióticos eficaces para este tipo de 
infecciones. Diferentes autoridades incluyendo la Unión Europea (UE), la Organización 
Mundial de la Salud (OMS) o las Naciones Unidas (NU) son conscientes de la gravedad 
de este problema y por ello están invirtiendo recursos económicos, estructurales y 
organizativos con el objetivo de resolver el problema de la resistencia a antibióticos. En 
este contexto, la Comisión de la UE lanzó una convocatoria en el año 2013 para 
promover el desarrollo de nanoterapias para el tratamiento de enfermedades 
infecciosas bacterianas.  
Uno de los proyectos seleccionados en esta convocatoria fue el proyecto PneumoNP, 
un proyecto colaborativo financiado bajo el Programa Marco FP7. El objetivo de este 
proyecto era desarrollar antibióticos basados en nanosistemas inhalables para el 
tratamiento de infecciones pulmonares causados por la bacteria Gram-negativa 
klebsiella pneumoniae. Estos nanosistemas estaban formados por péptidos 
antimicrobianos (que son los principios activos o fármacos) unidos a diferentes 
nanovehículos. En paralelo, el proyecto también pretendía desarrollar un nuevo 
sistema de nebulización para la administración de aerosoles a pequeños animales 
(ratas) y la validación de un kit de diagnóstico.  
El consorcio estaba formado por 11 socios de 6 países europeos diferentes (España, 
Italia, Francia, Alemania, Holanda y Dinamarca) procedentes de diferentes disciplinas 
científicas y tecnológicas. Dos de estos socios, SetLance srl (SET, Italia) y Adenium 
Biotech (ADE, Dinamarca) fueron los encargados de desarrollar los nuevos péptidos 
antimicrobianos. Otros dos socios, CIDETEC (CID, España) y la Universidad de Utrecht 
(UU, Holanda), se dedicaron a la preparación de los nanovehículos y al desarrollo de 
estrategias para la formación de los nanosistemas. Uno de los socios, Ingeniatrics 
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Tecnologías (INGEN, España), estaba al cargo del desarrollo del sistema de 
nebulización para la administración de los aerosoles a los roedores (ratas). Por último, 
Pathofinder BV (PAT, Alemania) y el Erasmus Medical Center (EMC, Holanda) 
estuvieron a cargo del desarrollo del kit de diagnóstico y de realizar estudios in vivo 
para evaluar la eficacia de los nanosistemas seleccionados en modelos animales 
relevantes, respectivamente.  
En este gran proyecto, el grupo de Radioquímica e Imagen Nuclear de CIC biomaGUNE 
(en el que se ha llevado a cabo la tesis doctoral) abordó dos objetivos principales: (i) 
evaluar el nuevo sistema de nebulización desarrollado por Ingeniatrics Tecnologías; y 
(ii) determinar la biodistribución y las propiedades farmacocinéticas de los 
nanosistemas desarrollados. Tal como se planteó inicialmente en la propuesta del 
proyecto, la evaluación debería realizarse utilizando técnicas de imagen nuclear como 
la Tomografía por Emisión de Positrones (PET, de sus siglas en inglés) o la Tomografía 
Computarizada de Emisión de Fotón Único (SPECT), en combinación con otras 
modalidades de imagen como la Tomografía Computarizada (CT).  
El trabajo llevado a cabo en este doctorado se ha dividido en tres partes, que 
corresponden a los capítulos 3, 4 y 5 del presente documento.  
En la primera parte del trabajo (Capítulo 3), se presenta el desarrollo de una nueva 
herramienta para la evaluación de la ventilación pulmonar en ratas sanas (wild type), 
utilizando la tecnología PET. A pesar de que esta tarea no se incluyó formalmente en la 
descripción inicial del proyecto PneumoNP y los resultados no se han utilizado en el 
contexto del proyecto, se considera como una herramienta esencial para trabajos 
futuros. De hecho, la evaluación de la biodistribución o determinación de las 
propiedades farmacocinéticas de nuevas entidades químicas/biológicas tras la 
administración pulmonar requiere evidencia previa de una ventilación no alterada, que 
puede evaluarse de manera eficiente y con alta sensibilidad con la herramienta 
recientemente desarrollada.  
La herramienta para la determinación de la ventilación pulmonar se basa en la 
utilización de dos gases radiofluorados ([18F]CF4 y [
18F]SF6), siguiendo una metodología 
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completamente innovadora. Estos gases son adecuados para este tipo de estudios, ya 
que no son tóxicos al ser químicamente inertes en condiciones fisiológicas y son 
prácticamente insolubles en sangre, evitando así la translocación a otros órganos. La 
metodología utilizada para generar estos radiotrazadores, consistió en un proceso de 
irradiación de protones en dos etapas (ver Figura 1): en la primera, el blanco del 
ciclotrón se rellena con oxígeno puro ([18O]O2) y se irradia con protones para generar 
el radioisótopo 18F (tiempo de vida media de 109.8 minutos) mediante la reacción 
nuclear 18O(p,n)18F. Tras recuperar el gas irradiado, se rellena el blanco con una mezcla 
de gases CF4/Ne o SF6/Ne (el neón se utiliza como gas portador). Mediante una 
segunda irradiación con protones (etapa 2) se promueve una reacción de intercambio 
isotópico entre los átomos de flúor del gas y el flúor-18 radiactivo, que queda 
absorbido en las paredes del blanco tras la primera irradiación, consiguiendo así el gas 
radiofluorado deseado. 
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Figura 1. Procedimiento seguido para la producción del gas [18F]CF4. En la etapa 1, el 
gas [18O]O2 (a) es irradiado con protones (b) para generar el isótopo 
18F (reacción 
nuclear 18O(p,n)18F), el cual permanece absorbido en las paredes del blanco (c y d). En 
la etapa 2, después de extraer el [18O]O2 (e), el blanco se rellena con una mezcla de 
gases CF4/Ne (f). Durante la segunda irradiación de protones (f), se generan iones (g) 
que en las condiciones de alta temperatura y presión dan lugar a la formación de 
[18F]CF4 (h).  
 
Siguiendo el procedimiento descrito y bajo las condiciones optimizadas se obtuvieron 
hasta 8.43±0.59 GBq de gas [18F]CF4 puro y 6.77±0.21 GBq de [
18F]SF6. Los ensayos 
destinados a determinar la utilidad de los gases radiofluorados como marcadores de 
ventilación pulmonar se llevaron a cabo en ratas. Para ello, se mezcló oxigeno gas 
(vehículo) con los gases radiactivos (cantidad total de radiactividad = 74±8 MBq) y 
estas mezclas fueron administradas a las ratas (ver Figura 2).  
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Figura 2. Ilustración del sistema de administración utilizado para llevar a cabo los 
experimentos de PET; (1) O2 gas; (2) jeringa hermética con gas radiactivo ([
18F]CF4 o 
[18F]SF6); (3) vaporizador de isoflurano; (4) vía de escape; (5) cámara PET-CT. 
 
Inmediatamente después, se llevaron a cabo estudios de imagen PET y se analizaron 
las diferentes curvas actividad/tiempo de cada sujeto. Como puede observarse en la 
Figura 3, estas curvas mostraban un aumento brusco de radiactividad justo después 
del inicio de la administración del gas radiofluorado. Cuando se interrumpió la 
administración, se logró una eliminación casi completa del gas de los pulmones en 
pocos segundos. Asimismo, las imágenes PET obtenidas en estos estudios mostraron 
una distribución uniforme del gas dentro de los pulmones.  
Debido a la alta eficacia del método de producción descrito más arriba, y a la semivida 
(o vida media) relativamente larga del Flúor-18, nuestros resultados sugieren que los 
gases fluorados podrían convertirse en herramientas muy útiles para el diagnóstico, el 
pronóstico o la evaluación de la respuesta al tratamiento para una amplia variedad de 
enfermedades pulmonares.  
1 L/min
10 mL/min
1
2 4
5
3
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Figura 3. a) Concentración de radiactividad (unidades arbitrarias, cuentas por minuto, 
CPM) en los pulmones en función del tiempo (promedio ± desviación estándar, n=2). 
(b)  Izquierda: imágenes PET-CT axiales de la cavidad torácica, antes (frames 1-4), 
durante (frames 5-15) y después (frames 16-19) de la administración del gas [18F]CF4; 
derecha: imagen CT en 3D del esqueleto corregistrado con la imagen PET en 3D de los 
pulmones (promedio de los frames 5-15).  
 
En la segunda parte del trabajo (Capítulo 4), se describe la evaluación del nuevo 
sistema de nebulización desarrollado por Ingeniatrics y la comparación de éste con 
otros dos sistemas de administración pulmonar comercialmente disponibles. Estos dos 
dispositivos eran por un lado, el generador de microspray de la de la compañía 
a
b
FRAMES 1-4 FRAMES 5-15 FRAMES 16-19
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PennCentury (FMJ-250 High Pressure Syringe Model, PennCentury. Inc. Wyndmoor, 
USA) y el nebulizador comercial de la compañía Aeroneb (Aeroneb® Lab Micropump 
Nebulizer). Para evaluar y comparar tanto la eficiencia de deposición como la 
distribución regional del aerosol tras la administración utilizando los diferentes 
sistemas, el aerosol fue previamente marcado con 2-deoxi-2-(18F)fluoro-D-glucosa 
([18F]FDG); este radiotrazador es ampliamente conocido en el ámbito clínico,  y se 
utiliza principalmente para el diagnóstico precoz y la evaluación de respuesta a 
tratamientos de diferentes tipos de cáncer. 
Tras la administración pulmonar del radiotrazador se llevaron a cabo estudios PET in 
vivo para determinar la distribución regional del aerosol utilizando los diferentes 
dispositivos. Tras adquisición de las imágenes, la cuantificación de las mismas se llevó a 
cabo mediante delineación de diferentes regiones de interés (ROIs) en las diferentes 
zonas de los pulmones, para posteriormente determinar la cantidad de radiactividad 
presente en dichas regiones. Paralelamente a los estudios de imagen, se llevaron a 
cabo estudios ex vivo, tanto para confirmar estos resultados como para evaluar la 
eficacia de los dispositivos en términos de deposición pulmonar de aerosoles. Con este 
fin, una vez finalizados los estudios de imagen se extrajeron los pulmones de los 
animales y se dividieron según los diferentes lóbulos. Finalmente, se midió la cantidad 
de radiactividad presente en dichos lóbulos utilizando una cámara de ionización/rayos 
gamma (WIZARD2 Gamma Counter, PerkinElmer, Waltham, USA). Al mismo tiempo, se 
determinó la eficiencia de deposición de cada método calculando la fracción 
depositada en los pulmones respecto a la cantidad administrada.  
Según los resultados obtenidos en los ensayos in vivo y ex vivo, la distribución regional 
del aerosol en los pulmones es homogénea cuando la administración se lleva a cabo 
con cualquiera de los nebulizadores (Ingeniatrics y Aeroneb), mientras que el patrón 
de distribución es muy irregular cuando la administración se lleva a cabo con el 
generador de miscrospray PennCentury. Por otro lado, los resultados de los ensayos ex 
vivo confirmaron que, utilizando cualquiera de los dos nebulizadores (Ingeniatrics o 
Aeroneb), solamente el 0.1% de lo nebulizado se deposita en los pulmones; por el 
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contrario, más del 85% de la fracción nebulizada termina en los pulmones cuando la 
administración se lleva a cabo mediante el microspray PennCentury. 
La tercera y última parte del presente trabajo (Capítulo 5) ha consistido en la 
evaluación mediante PET del tiempo de residencia en el pulmón de los dos péptidos 
antimicrobianos desarrollados por los socios SET y ADE tras la administración 
pulmonar, bien en su forma libre o conjugados con diferentes nanovehículos. En 
primer lugar, se estudiaron diferentes estrategias para incorporar un radioisótopo 
emisor de positrones o de fotones gamma a los diferentes compuestos (péptidos y 
nanovehículos). Puesto que los péptidos desarrollados por SET y ADE incorporaban una 
unidad tirosina, se optó por una estrategia de radio-yodación por sustitución 
electrofílica aromática, utilizando yodo-124 (isótopo emisor de positrones con una vida 
media superior a los 4 días) para permitir los estudios de imagen. Asimismo, uno de los 
nanovehículos se marcó mediante formación de un complejo agente quelante-
radiometal, utilizando para ello galio-67, emisor de fotones gamma con una vida media 
de algo más de tres días.  
Una vez implementadas las estrategias de marcaje, tanto los péptidos como los 
nanovehículos como sus combinaciones fueron administrados en ratas wild type 
utilizando el generador de microspray PennCentury (que se consideró el sistema más 
adecuado en el contexto de este proyecto, tras analizar los resultados incluidos en el 
capítulo 4) y se llevaron a cabo estudios de imagen para determinar el tiempo de 
residencia en los pulmones tanto de los péptidos marcados como de los nanovehículos 
seleccionados.  
Estos estudios confirmaron que las técnicas de imagen nuclear son adecuadas para la 
investigación preclínica de nuevas nanomedicinas, y que las propiedades 
farmacocinéticas de los fármacos pueden alterarse significativamente mediante el uso 
de nanovehículos. 
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Chapter 1. General introduction 
1.1. Nanoparticles and nanomedicine 
1.1.1. Nanoparticle: definition and applications 
Nanoparticles (NPs) are generally defined as particles between 1 and 100 nanometres 
(nm) in size, in at least one dimension. Due to their small size and large surface area, 
nanoparticles (NPs) have physico-chemical properties that differ from bulk materials or 
larger mesh powders, which make them attractive as e.g. catalysts (1), food additives 
(2), semiconductors (3) or additives for cosmetics (4), among others. In addition, by 
appropriate modification of their surface, NPs can become stable in water and 
biocompatible, and can be functionalised with bioactive tags which facilitate selective 
or preferential interaction with specific receptors or transporters. Because of this, they 
have emerged as potential drugs or drug-delivery systems. 
1.1.2. NP types 
NPs can be made from a large number of materials including proteins, peptides, 
polymers, lipids, metals and metal oxides, and carbon. In addition, NPs of multiple 
sizes and shapes can be prepared. As a consequence, there are different options to 
classify NPs, based e.g. on their properties, structure, size, etc. In this thesis, only 
polymeric NPs will be described to some extent, as these are the NPs that have been 
used in the experimental part. The description of the other types of NPs is out of the 
scope of this chapter, although excellent reviews can be found in the literature (5).  
1.1.3. Polymeric NPs 
Polymeric nanoparticles (PNPs) have received increased attention in biomedicine, 
where they are frequently used to improve the therapeutic worth of drugs and 
bioactive molecules by improving their bioavailability, solubility in physiological 
environment and retention time in the target organ or tissue (6, 7). Polymeric 
nanoparticles are optimal carriers for drug delivery due to their tunable characteristics 
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and high capacity to entrap, dissolve, or be attached to drug molecules or other active 
principles, overcoming thus limitations of traditional therapies such as low absorption 
of drugs, short biological half-life, low specificity and un-desired side effects. During 
the last years, many efforts have been done to render PNPs suitable for in vivo 
applications. Materials used for nanomedicine should fulfil several requirements 
including high biocompatibility and biodegradability, low toxicity, appropriate 
elimination and ease of processing (8).  
Polymeric nanoparticles can be made of either synthetic or natural polymers, although 
synthetic polymers present certain advantages, as (i) they can be tailored to give a 
wider range of desired properties, such as controlled linearity/branching, 
hydrophobicity, or molecular weight; (ii) they frequently show good biocompatibility 
and biodegradability; and (iii) they result in better lot-to-lot uniformity than natural 
materials (9).  
Different types of synthetic polymers have been used to prepare PNPs with application 
in biomedicine, including polyesters, polyurethanes, polyacrylamides and poly(amino 
acids)  (10). Among these, the aliphatic polyesters polylactic and polyglicolic acids as 
well as their copolymer poly(lactic-co-glicolic) acid (PLGA) have been approved by the 
Food and Drug Administration (FDA) for drug delivery and biomedical applications. 
These polymers undergo complete biodegradation in physiological medium via 
hydrolytic degradation of the ester linkages, resulting in the formation of the original 
monomers and lactic and glycolic acids, which are rapidly metabolized (11).  
Amphiphilic block copolymers, formed by two types of monomers or polymeric chains, 
typically one hydrophilic and one hydrophobic, have been also increasingly utilized. 
Examples of these kind of copolymers are polyesters, poly(amino acids) or poly(acrylic 
acids) covalently bound or copolymerized with polyethylene glycol (PEG) (12-14). 
Natural polymers including polysaccharides (15), dextran (16), chitosan (17), and 
alginate (18), among others, have also been applied to the preparation of PNPs (19-
21). They are generally non-toxic, exhibit high biodegradability and biocompatibility 
and they are often ready for use without expensive preparation/purification steps.  
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Polymeric NPs can be classified in different groups, according to their structure: 
Polymeric nanospheres, polymersomes, nanocapsules and micelles (Figure 1.1).  
 
Figure 1.1. Different polymeric nanoparticles and their general characteristics. 
Adapted from (22). 
Polymeric nanospheres are solid colloidal particles in which the polymer establishes a 
uniform matrix like in a frozen state, and can be prepared using different methods, 
including emulsion polymerization (23), emulsion/solvent evaporation or diffusion 
(24), salting out techniques (25) and nanoprecipitation (26). In nanospheres, which 
frequently present a hydrophobic surface, drugs can be either entrapped-in or 
adsorbed-on the polymer matrix. One subtype of polymeric nanospheres is single 
nanosphere
polymersome
nanocapsule
Copolymer unimers in a 
“frozen” state
Phase-separated solid 
matrix core
Copolymer unimers
assembled in a bilayer 
around an aqueous 
reservoir
Copolymer unimers or 
membrane surrounding 
a drug reservoir or oily 
core
micelle
Aggregated copolymers 
in dynamic equilibrium 
with unimers
Mobile fluid-like core
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chain polymeric nanoparticles (SCPNs), which production is based on the controlled 
compaction of single polymer coils into unimolecular soft nano-objects. Single chain 
polymeric nanoparticles, which have been assayed as drug carriers in the context of 
this PhD thesis, can be made of synthetic polymers, benefiting thus from the possibility 
of a controlled construction of the precursors in order to tune the size and 
functionality of the final particles (27), as well as from biocompatible, non-toxic and 
ready-to-use natural polymers. Synthetic routes to SCPN are mainly based on intra-
chain homo- and hetero-coupling or crosslinker-induced collapse of pre-functionalized 
polymers through covalent, dynamic covalent, and non-covalent bonding (28). Most 
covalent strategies require organic solvents and the reactions need to be carried out 
using highly diluted polymer solutions, at high temperatures and/or in the presence of 
metal catalysts, although this can be mitigated e.g. by using polymers with side-chain 
functionalities like oligo(ethylene glycol) (OEG) brushes which prevent intermolecular 
cross-linking (29). Recently, the group of Dr. Loinaz, co-director of this PhD thesis, has 
reported strategies to generate SCPN (30-32), and hence SCPNs have been also 
assayed (see Chapter 5).   
Polymersomes are vesicular nanosystems in which the core consists of an aqueous 
phase and the surrounding coating is a bilayer formed by an amphiphilic block 
copolymer. The vesicular structure is similar to the cellular membrane, in which the 
hydrophobic tails of the polymer or the lipid are oriented towards each other while the 
heads are in contact with the aqueous phases, both in the core and in the surrounding 
environment (33). Polymersomes are suitable for the encapsulation and subsequent 
delivery of water soluble drugs in the aqueous core, and are prepared using the so-
called film rehydration technique (34).  
Nanocapsules are similar to polymersomes with some differences, mainly: (i) the 
nature of the core, which in the case of nanocapsules is an oily phase, and (ii) in the 
surrounding polymer, which is not a bilayer but a single layer (35). Nanocapsules are 
useful for encapsulation of hydrophobic drugs, thus enhancing their bioavailability. The 
methods for the production of nanocapsules include interfacial deposition and solvent 
displacement (36, 37).    
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Micelles are formed by amphiphilc polymers brought into contact with an aqueous 
solution. At the critical micelle concentration (CMC), the amphiphilic moieties self-
assemble into nano- or micro-sized particles, in which the hydrophilic portion is 
oriented towards water and the hydrophobic part is oriented towards the inner core of 
the particle. The inner core, which is integrated by the hydrophobic regions, is able to 
host small lipophilic drugs. Polymeric micelles can be constructed by using both 
biocompatible synthetic polymers and natural macromolecules, thus combining the 
processability and adaptability of the first with the ability of the latter to program 
assemblage mechanisms and control the structure and function (38). Several polymers 
have been used to achieve effective steric stabilization of micelles.  
Poly ethylene glycol (PEG) is widely chosen as shell-forming segment for developing 
polymeric micelles because of its hydrophilicity, linearity, chain flexibility, lack of 
charge, and availability in a wide range of molecular weights (MWs) with narrow MW 
distribution, facilitating the preparation of narrowly distributed block copolymers 
capable to assemble monodisperse polymeric micelles with low polydispersity index 
(PDI). Additionally, the end-groups of PEG can be controlled to prepare block 
copolymers or branched polymers, or even to attach ligand molecules (e.g. targeting 
moieties). Typically, PEGs with 1−20 kDa are used for constructing self-assembled 
nanostructures (39). Besides PEG, other polymers have been applied as shell-forming 
segments for the preparation of polymeric micelles, including poly(N-vinyl-2-
pyrrolidone) (PVP) (40), poly(vinyl alcohol) (PVA) (41), and poly(acrylamide) (PAAm) 
(42), among others.   
The composition of the core-forming segment is essential for the stabilization of the 
micelle and eventually the drug cargo. For constructing cores containing hydrophobic 
drugs, the most commonly used polymers are polyethers (43, 44), polyesters (45, 46), 
and polyamino acids (38). For a recent review regarding the preparation and 
applications of polymeric micelles, please refer to (47). Polymeric micelles are the 
second type of carrier that has been used in the context of this PhD thesis. More 
information about the preparation method and properties is included in chapter 5.   
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1.1.4. NPs in Nanomedicine: Oncology 
Nanoparticle formulations are being deeply investigated in the field of biomedicine, 
mainly as therapeutic agents in oncology; this is due to three factors: (1) their size, 
which enables preferential accumulation in the tumour tissue (see below); (2) their 
high surface-to-volume ratio, which enables multi-functionalization; and (3) the 
possibility to load a high amount of cargo, which turns NPs into ideal drug carriers. It is 
commonly accepted that NPs preferentially accumulate in tumour tissue due to the 
well-known enhanced permeability and retention (EPR) effect (48). This effect is based 
on the presence of leaky vasculature in the vicinity of tumours, whose endothelium is 
fenestrated with gaps between 100 nm and 780 nm in size. This, together with a 
deficient lymphatic drainage, results in a passive accumulation of NPs in tumour tissue 
(see Figure 1.2a). Such accumulation can be even improved by attaching targeting 
moieties to the surface of the NPs, with high affinity for specific receptors over-
expressed in tumour cells but not in the surrounding healthy tissue. Because multiple 
targeting moieties can be attached to each individual NP, multiple interactions with 
the receptors present at the cell surface lead to improved retention and, eventually, 
internalization of the NP (49-51).  
This said, it is important to remark that both EPR effect and the concept of targeted 
nanomedicine in oncology are often overrated and/or misinterpreted. The EPR effect is 
indeed a highly heterogeneous phenomenon, which varies substantially from tumour 
model to tumour model, from patient to patient and also from one region to another 
within the same tumour (52). Hence, extravasation of the nanomedicines will follow a 
heterogeneous pattern. Additionally, nanomedicines find different barriers during 
extravasation, including pericyte-, smooth muscle cell- and fibroblast-based cell layers 
between endothelial and tumour cells. Once the NPs succeed in leaving the blood 
vessels, the extravasated NPs need to penetrate the interstitium to reach cancer cells. 
Due to their large size (when compared to small-molecule drugs) their penetration is 
hampered due to the high cell density usually found in tumours together with the high 
interstitial fluid pressure (Fig 1.2b). 
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Figure 1.2. (a) Schematic representation of an idealized passive accumulation of NPs in 
tumours by EPR effect. Tumours possess leaky blood vessels than allow extravasation 
of NPs, which can reach tumour cells; (b) realistic model: NPs need to cross pericyte-, 
smooth muscle- and fibroblast-based cell layers before they are able to bind to cancer 
cells. Once there, high cell density and interstitial fluid pressure need to be overcome 
before the NPs reach tumour cells.  
As a consequence of the above mentioned issues, incorporating targeting ligands in 
nanomedicine formulations is less useful than expected a priori (53). Indeed, the 
primary mode of tumour accumulation relies on EPR-mediated passive extravasation. 
After leaving tumour blood vessels and penetrating into the interstitium, NPs can find 
tumour cells and bind to them. Only at this stage the presence of the targeting moiety 
can contribute to enhance cell uptake. Hence, incorporation of targeting moieties to 
SMOOTH MUSCLE CELLPERICYTES FIBROBLAST
a
b
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improve accumulation in the target tissue or organ only makes sense in a limited 
number of specific cases, whereas in other cases, it just complicates and increases the 
cost of the formulation. For example, it has been shown that HER2-antibody targeted 
nanosystems do not increase tumour concentrations as compared to passively 
targeted formulations (54), although alterations on the local distribution of the agents 
within tumours was observed together with a higher degree of cell internalisation. 
1.1.5. NPs in Nanomedicine: Bacterial respiratory infection 
Besides the classical and widely explored (and exploited) application in oncology, the 
use of nanomedicines is also gaining attention in other therapeutic areas, and one of 
these is for the treatment of bacterial respiratory infections, which predominate over 
viral infections in secondary and tertiary care (55). Although effective antimicrobial 
treatments are available, pathogenic bacteria continue to demonstrate their ability to 
adapt to different types of antimicrobial compounds, increasing thus antibiotic 
resistance (56), while relatively few new candidate antibiotics reach the market. In 
view of this, global authorities are investing money by focusing on several key 'One 
Health' action areas, which include the development of new antibiotics and treatment 
strategies, among other actions.  
Together with the development of new, more potent antibiotics, such as  antimicrobial 
peptides (AMPs) (57), some emphasis has been made in the administration route. 
Intravenous and/or oral administration usually results in a low accumulation of the 
drug in the target organ or tissue, and consequently in a high accumulation in non-
targeted organs. This, ultimately, may result in undesired toxicity (58) together with 
enhanced selection of antibiotic-resistant bacteria residing in the endogenous 
microbiota, so-called collateral damage (59). To overcome this problem, local 
administration of the antibiotics has been considered, especially when the lung is the 
target organ as it is the case in bacterial respiratory infections. The accurate delivery of 
antibiotics into the lungs would allow the antibiotics to reach higher local 
concentrations, avoid ‘first-pass’ metabolism and reduce the toxic side-effects 
associated with systemic administration (60). However, for the majority of antibiotics, 
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direct lung administration results in a short residence time of the antibiotic in the lungs 
due to pulmonary clearance, enzymatic/chemical degradation and rapid adsorption. 
These drawbacks could be overcome by using appropriate nanocarriers to deliver the 
antibiotics, resulting in: (i) an increase in the drug concentration in the target organ at 
a lower dose; (ii) Protection of the antibiotic from enzymatic/chemical degradation; 
and (iii) protection of the antibiotic from pulmonary clearance mechanisms. 
Eventually, controlled released of the drug could be even achieved.  
In principle, a wide variety of nanocarriers could potentially be utilized to enhance the 
deposition of antibiotics to lung (61). However, the choice of the nanocarrier is 
restricted by the architecture of the respiratory tract and biological clearance 
mechanisms; it is commonly accepted that, when targeting the lower airways, 
nanomedicines with an aerodynamic diameter of 1–5 μm are deposited efficiently 
(62), which means that micron-size agglomerated nanomedicines or aerosols are 
currently mainly used for the pulmonary delivery of nanomedicines (63, 64).    
1.2. Tracing NPs in vivo: nuclear imaging techniques 
1.2.1. The need for tracking 
Nanomedicines need to fulfil certain prerequisites which include good 
biocompatibility, sufficient blood residence time to reach the target (when 
intravenously administered), efficient clearance from the body, and high accumulation 
in the target organs as well as low accumulation in off-target sites to minimize side 
effects. This, together with a good understanding of the pharmacokinetics and the 
biological fate of the nanomedicine and its integral parts, this is, the nanocarrier and 
the drug itself, is paramount to safely and efficiently tackle therapeutic experiments in 
the clinical arena with an appropriate selection of the dosing regimen.  
One particularly problematic aspect in the study of the biological fate of 
nanoformulations is that they are extremely difficult to detect and quantify once 
distributed in a material or biological system. One alternative to overcome this 
problem consists of labelling the nanoformulation with radioisotopes which allow their 
Chapter 1. General introduction 
 
10 
 
detection with high sensitivity and in a non-invasive fashion by using molecular 
imaging techniques such as single-photon emission computed tomography (SPECT) and 
positron emission tomography (PET). Both techniques are non-invasive and fully 
translational and enable the evaluation of pharmacokinetics both in the preclinical and 
clinical fields (65-72). 
1.2.2. Nuclear imaging: general aspects 
Nuclear imaging techniques rely on the administration of trace amount of a compound 
that is labelled with a positron or gamma-emitting radionuclide. When a positron or 
gamma-emitter disintegrates, gamma rays are ultimately generated. These gamma 
rays (or high energy photons) can be detected by specific equipment in such way that 
the original concentration of the compound can be accurately quantified. In this 
manner, as long as the radioisotope remains bound to the compound, the 
biodistribution of the latter within a living organism can be assessed. In other words, 
nuclear imaging techniques enable the absolute quantification of the concentration of 
a radionuclide (or the compound labelled with the radionuclide) over time, in vivo, 
non-invasively and with high sensitivity.  
1.2.3. Radioactive isotopes 
In general, there are two different types of radioisotopes which are commonly used in 
nuclear imaging: gamma emitters and positron emitters. These radioisotopes differ in 
their route of decay (Figure 1.3); single-photon emitters decay by emitting gamma rays 
which generally have energies in the range of 100-300 keV. On the other hand, the 
positron is the antiparticle of the electron, with equivalent mass but positive electrical 
charge. When a positron emitter disintegrates by spontaneous radioactive decay, the 
positron is emitted. During its short lifetime, the positron interacts with other charged 
particles and progressively loses its kinetic energy while describing a random path. 
When most of its energy has been lost, the positron annihilates with an electron of a 
surrounding atom, resulting in the emission of a pair of gamma rays traveling 180° 
apart and with energies of 511 keV each. The linear distance between the locations 
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where the disintegration and the annihilation occur is called positron range and is 
typically of a few millimetres in water.  
 
Figure 1.3. Schematic representation of radioactive decay by gamma (top) and 
positron (bottom) emission. 
Gamma and positron-emitters have different physical properties, the most notable 
being the half-life (T1/2). The half-life of a radioisotope is defined as the period of time 
required to decrease the number of radioactive atoms to one half of the starting value. 
In general, most single-photon emitter radioisotopes present longer half-lives (from a 
few hours to days; see table 1.1) compared to positron emitters (from a few minutes 
to hours; see table 1.2). The selection of a radionuclide with an appropriate half-life is 
paramount to guarantee successful in vivo studies. In general, the physical half-life of 
the radionuclide should match the biological half-life of the molecule to be 
investigated. If the physical half-life is too short, only partial information about the 
pharmacokinetics will be obtained. If the half-life is too long, a high (and unnecessary) 
radiation dose will be imposed on the subject under investigation. The latter is 
especially relevant in clinical studies.   
Table 1.1: Typical single photon emitters (with half-life and energy) 
Isotope Half-life γ Energy (γ Fraction) 
99mTc 6.02 h 141 keV (89%) 
123I 13.22 d 159 keV (83%) 
111In 2.80 h 171 (91%), 245 keV (94%) 
67Ga 3.26 d 93 (39%), 185 (21%), 300 (17%), 394 keV (5%) 
131I 8.02 d 364 keV (82%) 
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Table 1.2: Typical positron emitters (with half-life and energy) 
Isotope Half-life β+ Energymax (β
+ Fraction)* 
18F 109.8 min 0.63 MeV (0.97) 
11C 20.4 min 0.96 MeV (1.00) 
13N 9.97 min 1.20 MeV (1.00) 
15O 122 seg 1.73 MeV (1.00) 
68Ga 67.6 min 1.89 MeV (0.89) 
* The positrons are not emitted with a unique energy. The energies of the positrons emitted 
by a radionuclide follow a Poisson distribution. The maximum value of the distribution is 
presented in the table.  
1.2.4. Gamma-ray detection 
In order to obtain information about the regional concentration of the labelled 
molecule after administration into a living organism, it is necessary to detect the 
gamma-rays emitted as a result of the disintegration process and to determine the 
direction of such gamma rays. Hence, many angular views (projections) need to be 
acquired to feed mathematical reconstruction algorithms in order to obtain 
tomographic datasets. This technique is also known as emission CT (ECT) which should 
not be confused with standard X-ray transmission CT in which the X-ray source is 
external to the specimen. 
As mentioned above, both PET and SPECT rely on the detection of gamma rays 
originated during radioactive decay of gamma and positron emitting radionuclides, 
respectively. However, due to their different physical characteristics, SPECT and PET 
scanners’ detection system is different. SPECT scanners typically consist of at least one 
gamma ray detection module and a collimator. The core of the detection module is 
normally a scintillation crystal which, when excited by a gamma ray, absorbs its energy 
and re-emits it in the form of a flash light, typically in the ultraviolet range. This flash is 
subsequently detected by a photo-electronic system which records its location in the 
crystal and its intensity, which is proportional to the energy of the incidental gamma-
ray. The collimator most commonly consists of a lead plate which has a large number 
of holes to stop all the rays that do not reach the detector in a given direction. Hence, 
the collimator forms a projected image of the radioisotope distribution on the surface 
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of the scintillation crystal. SPECT systems are typically composed of one or more 
detection heads which are set up in a gantry that rotates around the imaged subject 
(Figure 1.4a). If only one static detection head is used, the technique is referred to as 
planar scintigraphy.  
In PET, the imaging strategy needs back-to-back detection heads and coincidence 
detection circuitry. Typically, PET scanners consist of a stationary array of a full-ring of 
detectors which simultaneously detect both gamma rays resulting from the positron-
electron annihilation. This kind of detection system is known as “electronic” 
collimation as opposed to the “physical” collimation implemented in SPECT scanners.  
A schematic representation of a PET scanner is shown in Figure 1.4b.    
 
Figure 1.4. Schematic representation of the detection of photons using SPECT (a) and 
PET (b) scanners. 
The physical collimation implemented in SPECT scanners hampers the detection of a 
large fraction of the gamma-rays emitted and, as a consequence, the absolute 
sensitivity (the ratio of detected to actual desintegrations) is much lower than in PET.  
Since the signal-to-noise ratio of the obtained data is proportional to the square root 
of the number of events detected, this has an enormous impact on the image quality, 
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as well as on the ability to acquire shorter scans to achieve improved temporal 
resolution and acquire multiple fields of view for whole body imaging.  
Both PET and SPECT systems acquire a set of projections at different angular positions 
around the specimen being imaged. Reconstruction tomography makes use of 
computers and mathematical algorithms to determine the unknown distribution of the 
radiotracer in the body from the detected projection data. The mathematical 
principles of image reconstruction fall beyond the scope of this PhD thesis. From a 
user’s perspective, reconstruction algorithms can be split into analytical methods, and 
most notably the Filtered Back Projection (FBP) algorithm; and the iterative statistical 
reconstruction method such as Ordered Subset Expectation Maximization (OSEM) and 
its many variants. Usually, iterative reconstruction methods provide images with 
improved spatial resolution and better signal-to-noise ratios at the expense of 
increased computational time and some unpredictability in the final outcome. For an 
extensive review about reconstruction methods, the reader is referred to (73-75). 
1.2.5. The key step: Radiolabelling 
Radiolabelling is a key step in the application of nuclear imaging techniques to the in 
vivo investigation of drugs and nanomedicines. So far, a huge number of strategies to 
incorporate both positron and gamma emitters to a wide range of molecular 
modalities (from small molecules to peptides, proteins, antibodies and NPs) have been 
developed. Here, only the most commonly used methodologies for the radiolabelling 
of NPs, together with the strategies commonly employed for the radiolabelling of 
peptides will be covered. For detailed reviews, the reader is referred to (76-78).  
1.2.5.1. Radiolabelling of NPs 
As mentioned in the previous sections, there is a large variety of NPs, and different 
radiolabelling strategies have been developed (79). However, they can be summarized 
in 2 main categories: 
The first category collects all the strategies that rely on the in situ generation of the 
radioisotope by activation of the NPs. This is usually achieved by irradiation with high-
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energy particles, i.e. ions (protons or deuterons) or neutrons. The high energetic 
reaction of the incident particle with a stable atom of the NP results in a nuclear 
reaction, which may lead to the formation of a radionuclide suitable for imaging 
studies. Some examples include the activation of Al2O3 NPs by proton irradiation via 
the 16O(p,α)13N nuclear reaction (80), the activation of  CeO2 NPs by deuteron 
irradiation via the 140Ce(d, p)141Ce nuclear reaction (81), and neutron activation of 
197Au NPs to generate in situ 198Au-labelled NPs (82). While the application of proton 
and deuteron activation is limited to NPs in the solid state and can result in thermal 
damage of the irradiated material, neutron irradiation can be conducted in solution, 
allowing the activation of nanoparticles or nanoparticle suspensions that are sensitive 
to thermal damage or radiation exposure (83). However, it is required that the NP to 
be activated contains a stable atom with a high capacity to interact with thermal 
neutrons. This property is limited to gold and a few more elements. As a consequence, 
direct activation is not usually applied to the activation of NPs with biomedical 
applications. Indeed, its use has been more restricted to the activation of metal and 
metal oxide NPs in toxicity studies.      
The second strategy is known as after-loading, and relies on the attachment or 
entrapment of the radionuclide once the NP has been synthesized. This is usually 
achieved using bifunctional chelators (BFCs), which contain one functional group and a 
metal binding moiety function. The functional group allows for anchoring the BFC to 
the surface of the NP, while the latter enables the sequestration of a metallic 
radionuclide. This strategy has been successfully applied to the preparation of NPs 
labelled with different positron and gamma emitters, including 64Cu, 68Ga and 99mTc 
(84-86). This methodology has one clear advantage: The NP can be designed to already 
contain the BFC and be submitted to full characterisation. The chelation reaction (for 
the formation of the radiometal-chelator complex) usually takes place under mild 
conditions, and hence it is expected not to significantly alter the NPs properties. 
Alternatively to the use of BFCs, the attachment of pre-labelled tags to the NP surface 
(69), attachment of radioactive ions (87) as well as diffusion of radioactive species into 
the NPs (88) have also been reported. In the particular case of liposomes, transport of 
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the radionuclide through the lipid bilayer using a hydrophobic complex and 
subsequent sequestration of the radionuclide in the inner aqueous phase has been 
commonly used (89, 90).  
As mentioned above, the second strategy (afterloading) is the most widely used in 
biomedicine, because the fact that the radionuclide can be incorporated in a very late 
stage in the synthetic process and the relatively mild reaction conditions required are 
definite advantages. In this PhD thesis, the labelling of polymeric NPs has been 
approached by formation of a radiometal-chelator complex, as discussed in detail in 
Chapter 5.   
1.2.5.2. Radiolabelling of peptides 
Radiolabelling of peptides has been typically approached by following two different 
strategies. The first strategy, commonly applied in classical nuclear medicine, relies in 
the attachment of a BFC to the peptide and subsequent incubation with a radiometal 
to form the corresponding complex (91). The second strategy is based on 
radioiodination, mainly using two different synthetic routes. The first one relies on the 
in situ oxidation of the anionic species (I-) using an oxidizing agent in solution, e.g. N-
chloro tosylamide or chloramine-T (92). This species subsequently undergoes 
electrophilic aromatic substitution (SEAr) reactions on aromatic rings containing 
electron-donating groups, this is, on tyrosine residues (which bear a hydroxyl group). 
This method results in high yields and has been widely applied to the radiolabelling of 
proteins and peptides. To prevent the degradation of the peptide/protein, milder 
oxidizing agents have been developed, such as 1,3,4,6-tetrachloro-3α,6α-diphenyl 
glycoluril (Iodogen) (93). The second labelling strategy is based on an indirect method, 
by covalent attachment of a pre-labelled prosthetic group, being the most commonly 
used the Bolton–Hunter reagent (94) which readily reacts with primary amines to form 
the corresponding amides.  
Besides radioiodination and BFC-radiometal complex formation, the attachment of 
pre-labelled tags using click chemistry approaches has recently gained attention (95, 
96) .  
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The AMPs evaluated in the context of the current PhD thesis were designed to contain 
at least one tyrosine residue. Because of this, the direct iodination method was 
employed (see Chapter 5 for details about experimental procedures).   
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Chapter 2. Motivation and objectives of the thesis 
2.1. Justification of the study: The PneumoNP Project 
As mentioned in Chapter 1, the majority of international stakeholders from the 
healthcare sector agree that infections due to antibiotic resistant Gram-negative 
bacteria are one of the major issues currently affecting global health, largely due to a 
lack of effective antibiotic therapy for this type of infection. Global authorities such as 
the European Union (EU), the World Health Organization (WHO) as well as the United 
Nations (UN) are aware of this problem and are investing money in trying to solve the 
worldwide endemic of antibiotic resistance by focusing on several key 'One Health' 
action areas. In this context, the EU Commission launched a call in 2013 encouraging 
the development of novel nanotherapeutics to treat bacterial infectious diseases.    
One of the projects selected for funding in this call was the PneumoNP project, a 
collaborative work funded by the European Commission under the FP7-NMP-2013-
LARGE-7 call (No. 604434 grant). The aim of the project was to develop a therapeutic 
system for the treatment of lung Gram-negative bacterial infections, based on the 
combination of an antimicrobial peptide (AMP) and a nanocarrier (NC) to yield the 
resulting nanomedicine (or nanosystem, NS), and focusing the attention on Klebsiella 
pneumoniae caused infections for proof of concept experiments. In parallel, the 
project aimed at developing a new nebulization system for the administration of 
aerosols in experimental animals and the validation of a diagnostic kit.  
The consortium as a whole included 11 partners from 6 member states (Spain, 
Germany, Italy, France, The Netherlands and Denmark) coming from different scientific 
and technological disciplines. Two of the partners, namely Setlance srl (SET, Italy) and 
Adenium Biotech (ADE, Denmark) were devoted to the development of novel AMPs. 
Two of the partners, CIDETEC (CID, Spain) and Utrecht University (UU, The 
Netherlands), were devoted to the preparation of nanocarriers and the development 
of strategies for the formation of the nanosystems. One of the partners, Ingeniatrics 
Tecnologías (INGEN, Spain), was in charge of developing the new nebulizer for the 
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administration of the aerosols to rodents. Finally, Pathofinder BV (PAT, Germany) and 
Erasmus Medical Centre (EMC, The Netherlands) were in charge of developing the 
diagnostic kit and performing in vivo proof of efficacy studies with selected NSs in 
relevant animal models, respectively.  
In this large project, The Radiochemistry and Nuclear Imaging Group at CIC 
biomaGUNE, in which this PhD has been conducted, had two major roles: (i) To 
evaluate the novel nebulization system developed by INGEN in comparison with 
commercially available systems; and (ii) to assess the biodistribution and basic 
pharmacokinetic properties of the nanosystems developed in the context of the 
project. As initially planned in the project proposal, evaluation should be conducted 
using nuclear imaging techniques, opportunistically in combination with other imaging 
modalities such as computerised tomography (CT).  
The piece of work included in this PhD comprises three parts, which constitute the 
three experimental chapters (chapters 3-5).  
In the first part of the work (chapter 3), a new tool for the assessment of lung 
ventilation using Positron Emission Tomography (PET) has been developed and 
evaluated in wild type animals (rats). This task was not formally included in the 
PneumoNP project description and the results have not been used in the context of 
the PneumoNP project. However, it is considered as an essential tool for future works. 
Indeed, evaluation of the biodistribution or determination of pharmacokinetic 
properties of new chemical/biological entities after lung administration requires 
previous evidence of unaltered ventilation, and this can be assessed efficiently and 
with high sensitivity with the newly developed tool. Hence, this work, which was 
published in Chemical Communications (1) and is included in Chapter 3 of this PhD 
thesis, will be paramount for future studies tackling lung diseases carried out at CIC 
biomaGUNE.  
The second part of the work, included in Chapter 4 of this PhD thesis, describes the 
evaluation of the new nebulization system developed by partner INGEN and its 
comparison towards two different commercially available systems. In the preclinical 
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context, in which experimental animals are used, the evaluation of innovative lung-
administered therapeutics requires administration of the drug in the form of aerosol or 
dry powder. Different technologies have been developed and tested, and none of 
them is ideal. Additionally, there is little information regarding the capacity of the 
different administration systems to release the drug in the lungs and the uniformity of 
the deposition. Hence, in this chapter, and by using a straightforward methodology to 
radiolabel the aerosol, the system developed by INGEN was evaluated in terms of 
uniformity of deposition of the aerosol in the lungs and the percentage of the aerosol 
that is actually released in the target organ. Both parameters are essential when 
planning therapeutic experiments. The performance of the new system was compared 
to an endotracheal insufflator and a commercially available nebulizer. This work was 
published in the European Journal of Pharmaceutics and Biopharmaceutics scientific 
journal (2), and the results were very useful in the selection of the administration 
system to be used in therapeutic experiments (carried out by partner EMC) and to 
establish the dose to be nebulised.     
In the third part of the work, which constitutes chapter 5 of the current PhD thesis, the 
residence time in the lungs of AMPs developed by partners SET and ADE after lung 
administration was investigated, both as free peptides and in combination with the 
nanocarriers, which were provided by partners UU and CID. With that aim, 
radiolabelling strategies to incorporate either positron or gamma emitters into the 
different species were developed, and imaging studies were conducted to determine 
the residence time in the lungs of the labelled AMPs and, eventually, of the 
nanocarriers. These studies provided clear information about the advantages of using 
nanocarriers as drug delivery systems for nanomedicines targeting the lungs, and the 
results were used in therapeutic experiments carried out at EMC. The work related to 
the radiolabelling of the AMPs and the radiolabelling of the NPs has been published in 
part in two different papers, in the journals Scientific Reports and Journal of Materials 
Chemistry B, respectively (3, 4). The manuscripts collecting other parts of the work 
developed in this chapter are currently under preparation. 
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2.2. Objectives 
The specific objectives of this PhD thesis are 
1. To develop an imaging tool for the quantitative assessment of lung ventilation 
in experimental animals using Positron Emission Tomography.  
2. To evaluate three different systems for the administration of aerosols to small 
rodents, in terms of: (i) Uniformity of the deposition within the lungs; and (ii) 
percentage of aerosol deposited in the lungs.  
3. To develop labelling strategies for the incorporation of positron emitters in 
selected antimicrobial peptides.  
4. To determine the residence time in the lungs of radiolabelled antimicrobial 
peptides, either administered as “free peptides” or combined with selected 
nanocarriers, after aerosol administration.    
5. To develop labelling strategies for the incorporation of gamma emitters in 
selected nanocarriers and evaluate their residence time in the lungs after 
aerosol administration.  
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Chapter 3. Development of novel tracers for the assessment of 
lung ventilation using Positron Emission Tomography 
3.1. Introduction 
As mentioned in previous chapters, pulmonary administration of drugs is extremely 
attractive, especially when the lung is the portal organ. However, in a real clinical 
scenario, the distribution of the drug over the whole lung relies on proper ventilation. 
Areas with impaired ventilation may result in low regional deposition, while 
hyperventilated areas may lead to local overexposure. In this scenario, it seems 
appropriate to evaluate, previously to the administration of the drug, the regional lung 
ventilation in order to identify those areas that may be submitted to under- or over-
exposure.  
In the clinical setting, the most accessible and economic tool to evaluate lung 
ventilation is spirometry, which provides information regarding the amount (volume) 
and/or speed (flow) of air that can be inhaled and exhaled. However, this routinely 
used function test is relatively insensitive to subtle changes and does not provide any 
regional information. Contrary to spirometry, in vivo medical imaging techniques have 
the potential to provide regional information in a non-invasive way. Unfortunately, the 
perfect imaging tool to quantitatively evaluate regional lung ventilation with high 
sensitivity and on real time has not been developed. 
One of the most convenient imaging techniques to assess regional lung ventilation is 
magnetic resonance imaging (MRI). This high-resolution technique uses the intrinsic 
signals generated from the underlying proton (1H) signal in tissues. Due to the low 
water content in the lung, MRI-lung imaging has severe limitations in terms of 
sensitivity. However, this limitation can be overcome by using exogenous contrast 
agents. For example, hyperpolarized (hP) gas MRI using the stable gaseous isotope 
helium-3 (3He) in combination with conventional MRI has offered hope to evaluate, 
noninvasively and with high sensitivity and excellent spatial resolution, the regional 
lung function together with structural integrity (1). For example, ventilation MRI 
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studies in humans using hP 3He allowed the visualization of ventilation defects in 
healthy volunteers, patients with asthma and lung-transplanted patients (Figure 3.1) 
together with the anatomical information of the lung structures (2). Unfortunately, the 
high cost and limited supply of 3He gas limit the dissemination of this technology (3).  
 
Figure 3.1. Static 3He gas density images from (A) a healthy volunteer, (B) a patient 
with asthma and (C) a lung-transplant recipient. The image from the healthy volunteer 
has a homogeneous signal intensity, while the asthmatic patients’ image has multiple 
“ventilation defects”. The image from the lung transplant recipient is homogeneous in 
transplanted (right) lung, and is markedly hypo-intense in the native emphysematous 
lung. Image obtained from reference (2). 
Alternatively to hP MRI, compounds containing a relatively large number of fluorine 
(19F, Larmor frequency 59.9 MHz) atoms per molecule can be used as gaseous contrast 
agents for ventilation 19F-MRI. Inert fluorinated gases, such as tetrafluoromethane 
(CF4), hexafluoroethane (C2F6), or sulfur hexafluoride (SF6), possess a T1 relaxation time 
of the order of milliseconds. The spin-rotation relaxation of these paramagnetic gases 
is so fast that the paramagnetism of oxygen has no effect. This short T1 makes rapid 
repetition radiofrequency pulses feasible. This enables the acquisition of a high 
number of signals, compensating for the low spin density of the gas (4). As a result, 
fluorinated gases have proven useful as lung contrast agents with sufficient MRI 
sensitivity (5). Additionally, availability of multiple litres of gas enables image 
acquisition during steady-state breathing. Among fluorinated gases, SF6 has the 
advantage that it is almost insoluble in blood, has no known toxic effects, is relatively 
inexpensive, and has been used for many years in clinical trials as part of the multiple 
inert gas elimination technique. 
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Despite high resolution images can be obtained with 19F-MRI, one of the main 
drawbacks arises from the poor intrinsic sensitivity of the technique; because of this, 
high concentration of contrast agent (in this case, fluorinated gas) needs to be 
administered. For example, in the first human study reported in the literature (see 
Figure 3.2) 19F-enhanced acquisitions were carried out following breath of a mixture of 
71-78% SF6 and oxygen (6). No adverse side effects were observed and the subjects 
tolerated the gas mixture well. However, because of the higher density of the 
fluorinated gas in comparison with the physiologically inhaled gases (O2, N2, CO2), 
transfer of data under normal ventilation conditions might be critical when compared 
with breathing ambient air.  
 
Figure 3.2. Left: Transverse image of a human lung after 3 breaths of 71% SF6. Right: 
coronal image of a human lung after 5 breaths of 78% SF6. Image obtained from 
reference (6). 
The limitations of MRI can be easily overcome by using more sensitive imaging 
modalities, such as nuclear imaging techniques, i.e. planar scintigraphy, single photon 
emission computerized tomography (SPECT) or positron emission tomography (PET). In 
nuclear imaging experiments, only trace amounts of the radioactive contrast agent 
(radiotracer) are required to provide enough signal-to-noise ratio. Additionally, 
absolute quantification of the distribution of the radiotracer after administration is 
feasible, especially in PET. 
In the clinical arena, lung ventilation is mainly performed with single photon emission 
computerized tomography (SPECT) or planar scintigraphy, using as contrast agents 
gases such as 81mKr (7) and more often radiolabelled aerosols generated either from 
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water-soluble agents ([99mTc]DTPA) (8) or solid particles (Technegas, or in situ 
generated 99mTc-labelled graphite particles) (9). After inhalation, 81mKr is distributed 
according to regional ventilation without any local accumulation on airway walls. 
However, limited access, short half-life (T1/2 = 13 s) and high cost restrict its use. Liquid 
radio-aerosols, and to a lower extent Technegas, show central airway deposition and 
peripheral “hotspot” formation in patients with obstructive lung diseases. Moreover, 
SPECT has limitations in terms of sensitivity, spatiotemporal resolution and image 
quantification. 
The higher sensitivity and quantitative nature of PET may result in a valuable 
alternative to other nuclear imaging modalities to assess lung ventilation. Compared to 
SPECT, PET offers much higher sensitivity and better spatial resolution (10). Taking 
advantage of these features, several methods have been developed to measure 
ventilation with PET. A continuous inhalation of 19Ne gas can be used to estimate 
regional ventilation (11). Due to the low solubility in water, its distribution volume is 
essentially that of the ventilated lung. A PET scan obtained when the distribution of 
19Ne is at equilibrium represents a balance between the amount of activity inhaled per 
unit time, its clearance by alveolar ventilation and radioactive decay. Alveolar 
ventilation can be thus calculated after determination of regional alveolar volume 
from regional density measurements (e.g., using CT). Alternatively, ventilation studies 
using 13N[N2] gas have also been reported (12). Unfortunately, the short half-life of 
Neon-19 (T1/2=17.4 s) and Nitrogen-13 (T1/2=9.97 min) restricts the application of these 
methodologies to those facilities equipped with a cyclotron and a radiopharmaceutical 
laboratory able to produce the radiolabelled gases.  
In this scenario, the development of inert, water insoluble, non-toxic gas labelled with 
a long-lived positron emitter would enable the preparation of the radiotracer in 
centralized production centres. Further distribution to surrounding hospitals equipped 
with a PET camera, in a similar fashion to 18F-labelled fluorodeoxyglucose ([18F]Fluoro-
2-deoxy-2-D-glucose or [18F]FDG), a radiotracer which is currently produced in the 
gigabecquerel (GBq) scale in many centres worldwide and utilized in the clinical setting 
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for the early diagnose of certain types of cancer and evaluation of response to therapy, 
can be envisaged. 
A suitable candidate for this purpose would be [18F]SF6. As mentioned earlier in this 
section, SF6 is almost insoluble in blood and has no known toxic effect. The production 
of [18F]SF6 might be approached by following a similar strategy to that already reported 
under non-radioactive conditions (13). Briefly, combustion of sulphur in [18F]F2 (which 
occurs at room temperature) would lead to the formation of a mixture of gases 
containing [18F]SF6 and small concentrations of lower fluorides, such as [
18F]S2F2 and 
[18F]S2F10. Subsequent purification comprising thermal decomposition of [
18F]S5F10 at 
400°C, by which procedure the tetrafluoride and hexafluoride are formed, thorough 
washing and alkali scrubbing to remove hydrogen fluoride and the hydrolysable lower 
fluorides of sulphur would probably yield pure [18F]SF6. Although this methodology 
looks feasible from a radiochemical point of view, it can be anticipated to be 
experimentally challenging and time-consuming.  
In this thesis, we envisioned the preparation of radiolabelled [18F]SF6 and also [
18F]CF4 
relying on a completely innovative methodology: radiotracer production within the 
cyclotron target, inspired by the method currently used for the in-cyclotron production 
of [18F]F2, which relies on the 
18O(p,n)18F nuclear reaction and involves two sequential 
irradiations (“double shoot method”). In a first step, the target is loaded with pure 
[18O]O2 and irradiated with protons, to generate 
18F (probably as anionic species) 
which remains absorbed on the walls of the target. The irradiated gas is then removed 
and the target is refilled with a mixture of F2 and neon. The second proton irradiation 
then drives a formal isotopic exchange of the fluorine in the gas with that on the target 
wall, resulting in the desired [18F]F2 (14, 15). This method can produce several tens of 
GBq worth of [18F]F2, and is becoming increasingly used worldwide.  
Our approach consists of filling the target with mixtures SF6/Ne or CF4/Ne (neon as a 
carrier) before the second irradiation, instead of the mixture F2/Ne. Our hypothesis 
relied on the fact that, due to (i) the high temperature and pressure achieved during 
irradiation; and (ii) the ionizing capacity of incident high-energy protons, isotopic 
exchange between one of the fluorine atoms in SF6 (or CF4) and 
18F atoms absorbed on 
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the target wall may occur, with consequent in situ generation of [18F]SF6 (or [
18F]CF4, 
see Figure 3.3). 
 
Figure 3.3. Two-step procedure for the production of [18F]CF4. In step 1, [
18O]O2 (a) is 
irradiated with protons (b) to generate 18F (18O(p,n)18F nuclear reaction), which 
remains absorbed on the target walls (c and d). In step 2, after removal of the [18O]O2 
(e), the target is filled with a mixture CF4/Ne (f). Under proton irradiation (f), ions are 
generated (g). Under high temperature/pressure, isotopic exchange and consequent 
formation of [18F]CF4 occurs (h). The parallel reaction pathway can be envisaged for the 
production of [18F]SF6. 
In parallel, a second strategy was also assayed. This was based on the direct irradiation 
of SF6/Ne or CF4/Ne mixtures (“single shot method”). In this approach, the hypothesis 
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is that the 19F can undergo 19F(p,pn)18F nuclear reaction, resulting in the formation of 
18F recoil atoms, which may lead to the isotopic exchange reaction with SF6 or CF4 
molecules to yield the desired labelled gases (see Figure 3.4).   
 
Figure 3.4. One-step procedure for the production of [18F]CF4. The target is filled with a 
mixture of CF4 and Neon (a), and is irradiated with protons (b) to generate recoil 
18F 
atoms (19F(p,pn)18F nuclear reaction), which can undergo directly isotopic exchange (c) 
and consequent formation of [18F]CF4 (d).  
The radiolabelled gases proved efficient as ventilation markers in healthy rodents, as 
demonstrated in our PET studies which showed uniform distribution of the 
radioactivity in the whole lungs and rapid elimination when the administration was 
discontinued.   
3.2. Objectives 
The specific objectives of this work are: 
1. To develop a method for the fast, efficient and reliable production of [18F]CF4 
and [18F]SF6 by proton irradiation of gas mixtures using the “double shoot 
method”  
2. To evaluate the suitability of the resulting radiofluorinated gases as contrast 
agents for the non-invasive evaluation of regional lung ventilation.   
D+
CF4
Ne
18Frecoil
[18F]CF4
a b
c d
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3.3 Experimental Part 
3.3.1 Production and analysis of [18F]CF4 and [
18F]SF6 
Two different strategies were used for the production of [18F]CF4 and [
18F]SF6. The first 
strategy (method A) was based on a single irradiation of a mixture CF4/Ne (production 
of [18F]CF4) or SF6/Ne (production of [
18F]SF6) with 18 MeV protons, using a commercial 
target for the production of [18F]F2, consisting of an aluminium target body with an 
internal volume around 50 mL (see Figure 3.5). Initial assays were carried out with CF4. 
The target was first filled with CF4 to a final pressure (P1) of 2-4 bar. The target was 
then topped with Neon to a final pressure of 20 bar and submitted to proton 
irradiation using a proton intensity of 15 µAh and an integrated current (C1) in the 
range 4-8 µAh. After finalising the irradiation, the target gas was transferred by 
depressurization to the radiochemistry laboratory and collected in a cryogenic trap 
cooled with liquid nitrogen. This strategy was also applied to the preparation of SF6. In 
this case, P1 was fixed to 4 bar and C1 was fixed to 4 µAh.  
The second strategy (method B) was based in a double shoot method using the same 
target. The process consisted of four steps: (i) The target was filled with [18O]O2 (P = 20 
bar) and was irradiated with 18 MeV protons using a proton intensity of 15 µAh and an 
integrated current (C2) in the range 1-4 µAh; (ii) after irradiation, the target gas was 
removed by cryogenic retrieval using liquid nitrogen; (iii) the target was filled with CF4 
(or SF6) to a final pressure of 4 bar, topped with Neon gas to a final pressure = 20 bar 
and irradiated with 18 MeV protons using a proton intensity of 15 µAh and an 
integrated current (C3) in the range 1-4 µAh; (iv) after the second irradiation, the target 
gas was transferred by depressurization to the radiochemistry laboratory and collected 
in a cryogenic trap cooled with liquid nitrogen. Parallel experiments were performed 
by adding a soda-lime trap before the cryogenic trap. For the production of [18F]SF6, C1 
and C2 were fixed to 4 µAh. In all cases, the amount of radioactivity collected in the 
cryogenic trap was measured in a dose calibrator (Capintec CRC®-25 PET, New Jersey, 
USA). Samples of the radioactive gas were withdrawn with a customized and 
automated syringe mounted on a syringe driver, and were analysed by gas 
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chromatography (GC) coupled to mass spectrometry (MS). Analyses were performed 
using an Agilent 7820A network GC connected to an Agilent 5975c inert XL MSD with 
triple axis detector. A J&W PoraPlot column (length: 27.5 m, internal diameter: 0.32 
mm) was used as stationary phase. The inlet conditions were 150°C, 6.8 psi and a flow 
rate of 2.5 ml/min. Helium (99.9999%) was used as the carrier gas. The oven 
temperature was set to 36°C. The analyses were made in scan mode. Eventually, a 
radioactivity detector (Gabi, Raytest) was connected via a post-column split to identify 
the radioactive gases.   
 
Figure 3.5. Configuration of the target and the recovery system used for the 
production of [18F]CF4 using methods A and B; (1) proton beam; (2) target chamber; (3) 
stainless steel-high pressure container and liquid nitrogen cooling bath; (4) Exhaust; (5) 
[18O]O2 gas bottle; (6) Neon gas bottle; (7) CF4 gas bottle; (8) stainless steel-high 
pressure container and liquid nitrogen cooling bath; (9) gas-tight syringe mounted on a 
syringe driver; (10) vacuum pump. V1-V10 are 2-way, normally-closed electro-valves. 
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3.3.2 Imaging studies 
Male rats (n = 2) weighing 350±14 g were used. Animal studies were approved by the 
ethical committee of CIC biomaGUNE and local authorities, and were conducted in 
accordance with EU Directives on animal ethics and welfare. Anaesthesia was first 
induced with 5% isoflurane in 100% O2. The animals were then moved to the PET/CT 
scanner (eXplore Vista CT, GE Helthcare) and anaesthesia was maintained with 
isoflurane in 100% O2 (1 L/min) administered through a face mask. Breathing 
frequency was adjusted to 50 ± 10 breaths/minute.  The PET acquisition (list mode, 
400-700 keV energetic window) was started, and 1 minute later the radioactive gas 
(74±8 MBq) was introduced in the O2 main stream (used in the anaesthesia system) 
over 70 s using a syringe pump (Figure 3.6).  
 
Figure 3.6. Configuration of the administration system utilised to perform PET studies; 
(1) O2 gas; (2) gas-tight syringe mounted on a syringe driver, containing the radioactive 
gas ([18F]CF4 or [
18F]SF6); (3) isoflurane vaporizer; (4) exhaust; (5) PET-CT camera. 
After the PET scan, a whole-body CT acquisition (140 mA/40kV) was performed. The 
PET list-mode data were formatted into 19 frames (3x20s, 10x10s, 4x20s and 2x30s) 
and PET images were reconstructed using the 2D-OSEM algorithm (2 iterations, 16 
subsets) into 175x175x61 arrays with a voxel size of 0.3875x0.3875x0.775 mm and 
were corrected for decay, scatter and random events. The CT images were 
reconstructed using a cone-beam Feldkamp algorithm into 262x262x688 arrays with a 
voxel size of 0.246 mm3. Images were analysed using PMOD image analysis software. 
Volumes of interest (VOIs) were manually drawn in the lungs on the CT images, 
1 L/min
10 mL/min
1
2 4
5
3
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transferred to the PET images and the concentration of the radioactivity was obtained 
for each time frame. All frames were finally summed in order to obtain more accurate 
images of the radioactivity distribution within the lungs. 
3.4 Results and Discussion 
3.4.1. Production and analysis of [18F]CF4 and [
18F]SF6 
When method A was used to produce [18F]CF4, higher P1 and C1 values led to higher 
activities, with a maximum of 0.80 ± 0.06 GBq for P1 = 4 bar/C1 =  8 µAh (Table 3.1). In 
this first approach (method A), we anticipated that irradiation of CF4 with protons with 
an appropriate energy should produce in situ recoil 18F atoms via the 19F(p,pn)18F 
nuclear reaction, capable to undergo isotopic exchange reaction with surrounding CF4 
molecules to form [18F]CF4. Cross sectional values for the nuclear reaction 
19F(p,pn)18F, 
which has an energy threshold of approximately 10 MeV and reach a maximum in 
cross-section values of around 150 mb in the range 20-30 MeV (16), suggest that the 
limiting step in the production of [18F]CF4 using method A is the generation of the 
radionuclide, which is limited due to the maximum energy available in our cyclotron 
(18 MeV). However, as it can be seen in Table 3.1 (entries 1-4), significant amounts of 
[18F]CF4 could be produced.  
When method B was used to produce the same labelled gas, constant C2 values led to 
equivalent values of radioactivity, irrespective of C3 (entries 5-7). However, a clear 
dependence between C2 and the final amount of radioactivity could be observed 
(entries 7 and 8). In this process, during the first irradiation of pure [18O]O2, 
18F is 
generated in high yield, because the cross section values of the nuclear reaction 
18O(p,n)18F have an energy threshold of around 2 MeV and reach a maximum at 
energies around 6 MeV (cross section values at this energy around 500 mb) (17). 
During cryogenic recovery of the 18O-enriched oxygen, Fluorine-18 remains absorbed 
on the walls of the target chamber, and is ready to undergo isotopic exchange reaction 
in the following step. Indeed, subsequent irradiation of CF4/Ne resulted in the 
formation of [18F]CF4. A clear correlation between the amount of [
18F]CF4 and the 
integrated current used for the first irradiation (entries 7-8, table 3.1) was observed, 
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suggesting that the formation of Fluorine-18 occurs majorly during the first beam, as 
expected.  Interestingly, the integrated current for the second irradiation had a minor 
effect on the amount of [18F]CF4, suggesting that the isotopic exchange reaction is 
relatively fast (see Table 3.1, entries 5-7).  
Table 3.1. Amount of radioactivity (mean ± standard deviation, n=3) decay corrected 
to the end of irradiation, obtained under different experimental conditions for 
production methods A (single irradiation) and B (double irradiation); NA: not 
applicable. 
Entry P1 (bar) C1 (µAh) C2 (µAh) C3 (µAh) A (GBq) 
1a
 
2 4 NA NA 0.27±0.03 
2a 2 8 NA NA 0.49±0.04 
3a 4 4 NA NA 0.58±0.04 
4a 4 8 NA NA 0.80±0.06 
5b NA NA 1 1 2.30±0.08 
6b NA NA 1 2 2.47±0.08 
7b NA NA 1 4 2.75±0.13 
8b NA NA 4 4 8.43±0.59 
a Production method A. b Production method B; P1: CF4 filling pressure 
under method A; C1: integrated current, method A; C2: integrated current, 
first irradiation, method B; C3: integrated current, second irradiation, 
method B. 
In previous works, the mechanism for the formation of [18F]CF4 was described as a 
result of a substitution reaction of a “hot” 18F atom with CF4, leading to the 
vibrationally excited molecule CF3
18F*, which ultimately deactivates by collision with 
the surrounding molecules leading to the formation of [18F]CF4 (18). In our case, when 
method B was used, the reaction mechanism should differ from that previously 
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described. During the second irradiation, the incident protons impact majorly in the 
gas, and hence hot 18F atoms are only produced by the 19F(p,pn)18F nuclear reaction. As 
can be seen in Table 3.1, the irradiation time for the second beam has a minor 
contribution to the final amount of [18F]CF4. Hence, we hypothesize that the ionic 
specie CF3
+, which is unreactive towards CF4, is formed during irradiation of the CF4/Ne 
mixture. This ion beam-induced ionic specie reacts with an 18F atom absorbed on the 
walls of the target chamber, leading to the rapid formation of [18F]CF4. In our hands, 
8.43±0.59 GBq of [18F]CF4 could be produced in short irradiation times. These results 
are extraordinary, especially considering that full optimization of the experimental 
conditions was not carried out. An increase in the CF4 filling pressure or application of 
higher integrated current values in the first irradiation may lead to higher production 
yields. 
Gas chromatography analysis showed the presence of two radioactive species at the 
end of the cryogenic trapping step, with retention times (Rt) of 1.93 and 2.53 min 
(Figure 3.7a), identified as [18F]CF4 and [
11C]CO2, respectively. Mass spectrometry 
analysis confirmed the presence of 5 major species with Rt = 1.45, 1.65, 2.25, 2.70 and 
3.92 min, corresponding to N2, CF4, CO2, C2F6, and C2F6O3, respectively (Figure 3.7c). 
One very minor peak appeared at Rt = 4.50 min, but the chemical structure could not 
be elucidated (Figure 3.7c, insert). [11C]CO2 could be easily removed by passing the 
irradiated gases through a soda lime trap before cryogenic trapping (Figure 3.7b), 
yielding radiochemically pure [18F]CF4 (Figure 3.7b).   
With the aim of proving the suitability of our method for the preparation of other 
fluorinated gases, the synthesis of [18F]SF6 was approached using the same 
experimental conditions (methods A and B) but replacing the CF4 gas bottle by an SF6 
gas bottle. Under method A, an integrated current of 4 µAh resulted in the formation 
of 0.36±0.05 GBq of [18F]SF6, while under method B, integrated currents of 4 µAh in 
both irradiations resulted in 6.77±0.21 GBq of pure [18F]SF6. The analysis of the 
radioactive gas by radio GC-MS after purification using a soda lime trap and cryogenic 
trapping confirmed the presence of only one radioactive species with Rt = 3.35 min, 
which was identified as [18F]SF6. MS analysis confirmed the presence of 4 species with 
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Rt = 1.45, 1.65, 1.70, and 2.95, that were identified with the mass spectra as N2, CF4, 
F3N, and SF6. A very minor peak appeared at Rt = 4.35 min, but the chemical structure 
could not be identified. These results are extremely positive, as they suggest that the 
strategy reported here might be extrapolated to the preparation of other radiolabelled 
fluorinated gases. 
 
Figure 3.7. (a, b) Chromatograms (radioactivity detector) corresponding to the analysis 
of [18F]CF4 before (a) and after (b) passing through a soda lime trap; (c) chromatogram 
(MS detector) corresponding to the analysis of [18F]CF4. 
3.4.2. Imaging Studies 
To prove the suitability of the radiofluorinated gases for the assessment of lung 
ventilation, in vivo PET studies combined with Computerised Tomography (CT) imaging 
were approached using [18F]CF4. In nuclear imaging, the administration protocol has to 
be defined according to the molecular or functional information of interest. Here, a 
simple administration protocol based on dilution of the radioactive gas (total amount 
of radioactivity = 74±8 MBq) in the carrier oxygen over ca. 70 seconds and acquisition 
of dynamic images (19 frames: 3x20s, 10x10s, 4x20s and 2x30s; administration of 
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[18F]CF4 starts at t=60 s) was applied in order to get a first proof of concept. The time-
activity curve in the lungs showed a sharp increase just after the onset of the 
administration of [18F]CF4 (Figure 3.8a). When the delivery was discontinued, almost 
complete elimination from the lungs was achieved in a few seconds. Time-averaged 
PET images clearly show uniform distribution of the gas within the lungs (Figure 3.8b). 
 
Figure 3.8. (a) Concentration of radioactivity (arbitrary units, counts per minute, CPM) 
in the lungs as a function of time (mean ± standard deviation, n=2); (b) Left: Axial PET-
CT slices of the thoracic cavity, before (frames 1-4), during (frames 5-15) and after 
(frames 16-19) administration of [18F]CF4; right: surface-rendered 3D-CT images of the 
skeleton corregistered with volume-rendered 3D-PET images of the lungs (Averaged 
frames 5-15). 
Considering the administration time (70 s) and average tidal volume of the rats, the 
total volume of inhaled/exhaled air during [18F]CF4 administration was estimated to be 
ca. 100 mL. The whole amount of radioactivity (74±8 MBq) was diluted in 1.16 L of gas 
a
b
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(O2 flow rate = 1 L/min; administration time = 70s); hence, the amount of radioactivity 
reaching the lungs can be estimated to be 6.3 MBq. In spite of the low amount of 
radioactivity, excellent images showing uniform distribution of the radiolabelled gas all 
over the lungs could be obtained. 
The use of inhaled gases as contrast agents has the advantage that, contrary to 
aerosols or labelled particles, gases distribute according to regional ventilation. The 
18F-fluorinated gas reported in this chapter has two major advantages: (i) the non-
radioactive analogue is chemically inert, non-toxic, and has poor solubility in water; 
hence, low translocation to the blood torrent and remote organs is expected. 
Additionally, the gas is rapidly exhaled. Altogether, these factors contribute to a 
minimisation of the radiation dose posed on the subject under investigation; and (ii) 
the relatively long half-life of 18F and the efficient production method reported here 
should enable centralized production and distribution to nearby imaging centres, 
facilitating a potential translation into the clinical setting, in a similar fashion to the 
currently established production/distribution network for the radiotracer 2-deoxy-2-
(18F)fluoro-D-glucose, commonly known as [18F]FDG.  
Currently, the gold standard used in the clinics for the assessment of regional lung 
ventilation is planar scintigraphy or SPECT using Technegas as the contrast agent. In 
this method, 99mTc-labelled graphite particles are generated and inhaled by the patient 
before entering the camera. After inhalation, the patient is subjected to an static 
imaging session and information about the regional ventilation (in 3D when SPECT is 
used, in 2D when planar scintigraphy is used) can be obtained.         
Besides the already mentioned limitations of SPECT in terms of sensitivity, resolution 
and absolute quantification, there are two significant drawbacks of this approach that 
are worth to mention. First, as already mentioned, the particles tend to accumulate in 
central airways and hypo-ventilated areas, due to convection effects. Second, the 
biological half-life of Technegas in healthy subjects is 135 hours (19), resulting in a high 
dose posed on the investigated subject. In this regard, our approach would contribute 
to a less invasive medicine. Although dosimetry studies have not been carried out yet, 
the rapid exhalation and the low dose required to obtain the images anticipate a 
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radiation dose for the patient much lower than that released with the current gold 
standard. Finally, it is worth mentioning that 99mTc is usually obtained from 99Mo/99mTc 
generators, being 99Mo produced in nuclear reactors. The radioactive gases proposed 
in our work are produced in a cyclotron, and hence represent an environmental 
friendly alternative to the current state of the art.   
3.5 Summary and Conclusion  
In summary, we report here the unprecedented, highly efficient, simple and easy-to-
automate preparation of [18F]CF4 and [
18F]SF6 following an ion beam induced chemical 
reaction based on a double proton irradiation approach. The general methodology 
reported here might be extended to other fluorinated gases. [18F]CF4 has proven 
suitable for the determination of regional lung ventilation using PET-CT. Due to the 
efficiency of the synthetic method and the relatively long half-life of Fluorine-18, the 
radiofluorinated gases reported here may become powerful tools in the diagnostic, 
prognostic or evaluation of response to treatment for a wide variety of lung diseases. 
The establishment of a production/distribution network to facilitate translation to the 
clinical setting can be foreseen. Future works will focus on the refinement and full 
optimization of the experimental set up, an extension of the methodology to the 
preparation of other 18F-fluorinated gases and the evaluation of the radiolabelled 
gases as ventilation markers using animal models of impaired lung ventilation. 
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Chapter 4. Evaluation of pulmonary administration methods in 
rodents using nuclear imaging techniques 
4.1. Introduction 
Lung administration of drugs has recently gained attention, especially when the lung is 
the target organ, e.g. to treat lung cancer or airway diseases such as asthma, cystic 
fibrosis and chronic obstructive pulmonary disease (COPD) (1). Pulmonary 
administration offers numerous advantages as a delivery route compared to oral or 
intravenous administration. On one hand, bioavailability of drugs can be enhanced, 
because contrary to gastrointestinal tract and liver, lung possesses limited intracellular 
and extracellular drug metabolizing enzyme activities (1). On the other hand, lung 
administration usually leads to higher absorption rate, reduced drug doses and rapid 
onset of action (1, 2).  
Critical endpoints in the development of a drug formulation are the preclinical studies 
conducted with various animal models (3). In the particular context of aerosols for 
inhalation, the administration into animals is a critical challenge especially in small 
rodent species, and only a few methods of administration have been developed so far. 
Endotracheal and intratracheal insufflations have the advantage that they enable 
specific deliver of the drug to the lung, with high predictability in terms of delivered 
dose. Additionally, compared to intratracheal administration (via an incision into the 
trachea), endotracheal insufflations are minimally invasive and can be used in 
repeated dose studies. Two major disadvantages of this method are the potential 
induction of lesions due to the introduction of the insufflators and the need to 
maintain the animals under anaesthesia during the administration, which can cause 
some problems in certain scenarios.  
Alternatively to endo/intratracheal insufflations, inhalation towers can be used for 
pulmonary administration of aerosols to small rodents. In this case, the aerosol is 
generated in a chamber and is incorporated into the lungs of the exposed animals 
through natural respiration; hence this method is perceived to result in a 
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homogeneous distribution of the aerosol within the lungs. Additionally, several 
animals can be exposed simultaneously. One major drawback of this alternative is the 
need to keep the animals under anaesthesia during long periods of time. This 
limitation can be overcome by establishing a training process to ensure that animals 
are accustomed to the exposure tubes (4), although this process is time-consuming 
and requires the participation of experienced personnel.   
Irrespective of the administration strategy, two critical factors have to be considered in 
lung administration: (i) the dose actually deposited in the lungs, which is critical when 
planning dose-dependent pre-clinical studies, such as toxicity, pharmacokinetics and 
efficacy studies (5); and (ii) the regional distribution within the lungs, which is of 
utmost importance because uniform distribution among the different lung lobes is 
required both to guarantee an effective treatment and to prevent toxic or side effects 
due to local, potentially harmful deposition of the drug.  
One of the main challenges in addressing the above mentioned points is that drugs (or 
the aerosols containing the drugs) are extremely difficult to detect and quantify once 
distributed in a biological system. One alternative to overcome this difficulty consists 
of labelling the drug or the aerosol with a fluorescent tag, enabling their localization in 
vivo using optical imaging techniques. For example, in a recent study a newly 
developed aerosol generator was tested for pulmonary administration to the lungs of 
mice and compared to an endotracheal insufflator (6), using Fluorescence Molecular 
Tomography (FMT) and ovalbumin as a model protein labelled with a fluorescent dye. 
In spite of the suitability of this approach, optical imaging techniques have severe 
limitations in vivo, mainly due to the poor penetration capacity of visible or infrared 
light in tissues, which limits the application of the technology to small rodents. 
Additionally, quantification of the images is extremely challenging. One alternative to 
overcome these drawbacks consist of labelling the drug or the aerosol with a positron 
emitter (7). The disintegration of the positron emitter leads ultimately to the 
generation of high energy gamma rays, which have virtually no penetration limits and 
can be externally detected and processed to generate three dimensional (3D)-images. 
Such images provide quantitative information about the spatiotemporal distribution of 
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the labelled specie (8). This approach has been applied to evaluate changes in the 
deposition of inhaled aerosols within the lung related to the presence of disease or 
resulting from inhalation challenge interventions or inhaled therapies in the clinical 
field (9). 
In the context of PneumoNP, and as previously mentioned, our consortium has 
developed novel nanosystems to treat drug-resistant lung infections, which had to be 
assayed in therapeutic experiments in a rat model using lung administration in aerosol 
form. In order to select the most convenient administration strategy, three different 
options were considered: (i) endotracheal insufflations using the PennCentury 
MicroSprayer® Aerosolizer; (ii) inhalation using a newly developed nebulizer; and (iii) 
inhalation using a commercially available nebulisation system, the Aeroneb® Lab 
Micropump Nebulizer (Aerogen, Dangan, Ireland). In all cases, the aerosol was labelled 
with 2-deoxy-2-(18F)fluoro-D-glucose ([18F]FDG), a radiotracer widely used in the 
clinical field for the early diagnose and evaluation of the response to treatment of 
different cancer types. For the three administration methods, the percentage of 
administered dose deposited in the lungs and the regional distribution of the aerosol 
within the lungs was evaluated using in vivo PET imaging and complementary ex vivo 
techniques such as dissection/gamma counting experiments, and eventually ex vivo 
PET imaging. Uniform deposition of the labelled aerosol within the lungs could be 
achieved using inhalation, while poorly-uniform distribution was often and 
unpredictably achieved when the MicroSprayer® Aerosolizer was used, although the 
latter resulted in almost quantitative deposition of aerosol in the lungs. 
4.2. Objectives 
The specific objective of this work is: 
1. To compare three different aerosol administration systems in wild type rats, in 
terms of: (a) uniformity of the regional distribution of the aerosol in the lungs; 
and (b) percentage of the nebulised dose actually deposited in the lungs.    
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4.3 Experimental Part 
4.3.1 Animal experiments: general 
All animal experiments described in the following sections were performed in 
accordance with the Spanish policy for animal protection (RD53/2013), which meets 
the requirements of the European Union directive 2010/63/UE regarding the 
protection of animals used in experimental procedures. All experimental procedures 
were approved by the Ethical Committee of CIC biomaGUNE and authorized by the 
local authorities. 
4.3.1.1. Aerosol administration 
Six-to–eight weeks-old female Sprague Dawley rats (Janvier, Le Genest-Saint-Isle, 
France) weighting ca. 225 g were used in all the experiments.  
4.3.1.2. Endotracheal insufflations 
Endotracheal insufflations were carried out using the Penn-Century MicroSprayer® 
Aerosolizer (FMJ-250 High Pressure Syringe Model, Penn-Century. Inc. Wyndmoor, 
USA; henceforth “Penn-Century Aerosolizer”; Figure 4.1). 
 
Figure 4.1. Left: Picture of the PennCentury Microsprayer; right: schematic illustration 
of the endotracheal administration procedure followed to perform the experiments. 
Image courtesy of Penn-Century, Inc.  
Deep sedation was induced to the animals (n = 6) by inhalation of 5% isoflurane in pure 
O2. The tip of the delivery needle was carefully positioned just above the carina and a 
pre-defined volume (established by using spacers in the syringe plunger) of injectable 
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[18F]FDG solution (Provided by Iba Molecular Spain and diluted with ultrapure water 
1:25; 50 µL; amount of radioactivity around 1.85 MBq) was administered. A small 
animal Laryngoscope (Penn-Century, Model LS-2) was used for correct visualization of 
the epiglottis. Immediately after administration, rats were divided in two groups 
(group 1: n = 3; group 2: n = 3), and submitted to in vivo and ex vivo imaging 
experiments, respectively (see below). 
4.3.1.3. Inhalation using an in-house developed aerosol generation system 
The aerosol inhalation system developed at Ingeniatrics Tecnologías (henceforth 
“Ingeniatrics nebuliser”) consisted of the following parts: (a) Aerosol generation unit 
with Flow Blurring® (FB) technology. Two different models were assayed. One of them, 
the FB240 nozzle, had an equal exit orifice diameter and inner tube diameter of 240 
m. The other nozzle (FB100) had an orifice and inner tube diameter of 100 m; (b) a 
peristaltic pump to push the labelled solution to be nebulised at a constant flow rate; 
(c) a compressed air supply, equipped with a pressure regulator and a pressure meter; 
(d) ON/OFF controlling device; (e) main nebulisation and distribution chamber; and (f) 
an exit outlet to prevent overpressure in the main chamber (see Figure 4.2).  
The nebuliser was placed at the bottom of the nebulisation chamber, which was 
directly connected to four rat holders coupled with rubber adaptors to enable 
appropriate positioning of the animals and only-nose exposure to the aerosol. An exit 
outlet was also installed at the top of the nebulisation chamber to avoid overpressure 
in the system and to trap the radioactive aerosol exiting the main chamber. For this 
purpose, two washing bottles were connected in series and a vacuum pump was 
installed to keep the system at slight under-pressure (-50 Pa), thus ensuring that all the 
radioactive material was properly trapped. 
To conduct inhalation studies, rats (n = 6) were anesthetized by an intraperitoneal (IP) 
injection of a mixture of medetomidine, midazolam and fentanyl (0.6, 6 and 0.02 
mg/Kg, respectively). Once animals were under sedation, they were introduced into 
identical cylindrical oro-nasal exposure holders. Then, a solution (1.5 mL) containing 
[18F]FDG (Provided by Iba Molecular Spain and diluted with ultrapure water 1:12; 
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amount of radioactivity: 370±10 MBq) was aerosolized using the system described 
above. After finalizing the exposure, animals were randomly divided in two groups 
(group 3: n = 3; group 4: n = 3), and submitted to in vivo and ex vivo imaging 
experiments, respectively (see below).  
 
 
Figure 4.2. Complete aerosol generation system setup for 4 rats: A) Nozzle (FB240 or 
FB100); B) Peristaltic pump; C) Synthetic air bottle; D) ON/OFF control device; E) 
nebulisation chamber with four rat holders and F) exit outlet.  
4.3.1.4. Inhalation using the Aeroneb® Lab Micropump Nebulizer 
For inhalation studies using the commercially available Aeroneb® Lab Micropump 
Nebulizer (henceforth “Aeroneb nebulizer”), animals (n = 6) were submitted to the 
same procedure as described above (section 4.3.1.2), using an inhalation configuration 
as depicted in Figure 4.3. Actually, the system used in our experiments was an 
adaptation of a device currently used in humans, the Aerogen® Pro nebulizer 
(Aerogen, Dangan, Ireland) and allowed exposure of one animal at a time, by using a 
rat nebulizer Delivery System (AG-ALSMHLD-RAT, Kent Scientific Corporation, 
Connecticut, USA). In this case, the generation of the aerosol relies in the presence of a 
vibrating membrane just below the nebulizer’s reservoir, enabling fast administration 
of medicines to patients with very low residual losses (10, 11). The droplet size can be 
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tuned by appropriate selection of the membrane’s pore size, which in our case was 
chosen to generate droplets within 4-6 µm in diameter. The air flow, used to push the 
aerosol towards the animal, was set to 100 mL/min. The total nebulised volume of 
[18F]FDG (Provided by Iba Molecular Spain and diluted with ultrapure water 1:4) was 
0.5 mL containing 370±10 MBq (total exposure time = 5 min). After exposure, animals 
were randomly divided in two groups (group 5: n = 3; group 6: n = 3), and submitted to 
in vivo and ex vivo imaging experiments, respectively (see below). 
 
Figure 4.3. Illustration of the Aeroneb Lab Micropump Nebulizer connected to the rat 
holder.  
4.3.2. Droplets size measurements 
Aerosols generated by different nebulizers were characterized using a Sympatec 
Helos/BF Magic laser diffraction system (HELOS, Sympatec, Clausthal-Zellerfeld, 
Germany; see Figure 4.4) at Ingeniatrics Tecnologías (Seville, Spain). In brief, the 
nebulizer was clamped into a stand and the mouthpiece exit of the nebulizers 
positioned ≈50 mm from the Fourier lens face and ≈100 mm from the laser beam. The 
formulation (appropriate dilution of completely decayed [18F]FDG solution with 
ultrapure water) was then nebulised through the laser beam. The measurements were 
performed with six runs of 100 ms duration each. The droplet diameter distributions 
were parameterised by their Mean Droplet Size Distribution (MDSD) and Geometric 
Standard Deviation (GSD).  
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Figure 4.4. Pictures of the Sympatec Helos/BF Magic laser diffraction system used for 
the assessment of aerosols’ droplets size measurements carried out at Ingeniatrics 
Tecnologías (Seville, Spain), using the FB240 (A) and FB100 (B) nozzles.  
4.3.3. In vivo imaging experiments 
Without recovering from sedation, animals from experimental groups 1, 3 and 5 were 
positioned in an eXploreVista-CT small animal PET-CT system (GE Healthcare, USA) to 
perform in vivo studies. For animals in groups 3 and 5, still under the effects of 
medetomidine/midazolam/fentanyl, no additional anaesthesia was required during 
image acquisition. For animals in group 1, anaesthesia was maintained with 1.5-2% 
isofluorane in pure O2.  
During imaging, rats were kept normothermic using a heating blanket (Homeothermic 
Blanket Control Unit; Bruker). Dynamic PET images (energy window: 400-700 KeV) 
were acquired with the following frames: 4 x 15 s, 4 x 30 s, 3 x 60 s and 3 x 90 seconds. 
In all cases, four beds were defined to acquire whole body images. After each PET 
acquisition, a CT scan (X-Ray energy: 40 kV, intensity: 140 µA) was performed for a 
later attenuation correction in the image reconstruction and for unequivocal 
localization of the radioactivity. Random and scatter corrections were also applied to 
the reconstructed image (filtered back projection reconstruction algorithm), 
generating a 175x175x220 dimension image, with a 2 mm axial FWHM spatial 
resolution in the centre of the Field Of View (FOV).  
PET-CT images of the same animal were co-registered and analysed using PMOD image 
processing tool. Volumes of interest (VOIs) were manually delineated on the whole 
lungs to assess the amount of radioactivity deposited in this organ. Additionally, small 
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spherical VOIs (diameter = 1 mm) were drawn in the different lung lobes and time–
activity curves (decay corrected) were obtained as cps/cm3 in each VOI. Curves were 
transformed into real activity (Bq/cm3) curves by using a calibration factor, obtained 
from previous scans performed on a phantom (micro-deluxe, Data spectrum Corp.) 
under the same experimental conditions (isotope, reconstruction algorithm and 
energetic window). For each curve, an exponential equation was adjusted and the 
amount of radioactivity in each region at administration time was calculated by 
extrapolation.  
4.3.4. Ex vivo imaging experiments 
Without recovering from sedation, animals from experimental groups 2, 4 and 6 were 
sacrificed by cervical dislocation immediately after administration of the labelled 
aerosol. In all cases, the time gap between the end of the exposure to the aerosol and 
the sacrifice time was less than 10 seconds. The respiratory system of the rats (trachea 
and both lungs) was fixed with formalin (10% formalin solution, neutral buffered) and 
subsequently harvested. PET-CT images of the extracted organs were acquired for 60 
minutes (n = 3 per group). Image reconstruction and analysis was performed as above, 
although in this case exponential curves were not adjusted because static images were 
acquired. After finishing the imaging session, the lungs were dissected into different 
lobes, and the amount of radioactivity in each lobe was accurately determined by 
gamma counting (WIZARD2 Gamma Counter, PerkinElmer, Waltham, USA). 
4.4 Results and discussion 
4.4.1. Aerosol droplet size measurements 
For inhalation, the most important characteristic of an aerosol is the respirable dose, 
which is the fraction of droplets in the respirable range. With the aim of having a 
homogeneous distribution along the whole respiratory track, main requirement in 
terms of droplet size is having a MSDS below 4 microns with a high percentage of 
droplets with a diameter in the range 0.9-5.25 μm (12).  
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The droplet size obtained after nebulization depends on the electrolyte concentration 
of the solution, as recently reported (Beck-Broichsitter et al. 2017). For this reason, in 
the current work the aerosol droplet size was determined with a proper dilution of the 
[18F]FDG solution with purified water, in order to obtain representative results for in 
vivo experiments. The [18F]FDG solution provided by IBA Molecular Spain contained 10 
mg/mL of NaCl, 1.5 mg/mL of NaH2PO4, and 0.4 µg/mL of ethanol, and dilutions with 
purified water 1:25, 1:12 and 1:4 were carried out to assess droplet size using the 
Penn-Century Aerosolizer, the Ingeniatrics nebuliser and the Aeroneb nebuliser, 
respectively.  
The aerosol generated with the nozzles developed at Ingeniatrics Tecnologías (FB240 
and FB100) was produced using a nebulizer based on Flow Blurring® technology. Flow 
Blurring® is a purely mechanical atomization technique that produces highly turbulent 
pre-mixing between gas and liquid streams. As a consequence of this special regime, 
very good quality aerosols with ultrafine droplets are obtained. Given a specific 
geometry design, droplet size distribution could be selected by choosing the proper set 
of operational parameters (pressure and liquid flow rate). Hence, several liquid flow 
rates and pressures were tested for the FB240 and FB100 nozzles, in order to produce 
aerosols in the respirable range (optimal conditions are shown in Table 4.1.). At these 
experimental conditions, both nebulizers were able to generate a high percentage of 
droplets in the desired range of 0.9-5.25 µm.  
The aerosol produced by the Penn-Century Aerosolizer resulted in significantly higher 
droplet size, in the range of 20 µm, which was in great accordance with the value 
specified by the manufacturer. In this case, only a small fraction (2.6%) of the droplets 
fell within the desired range (0.9-5.25 µm).  
Evaluation of the droplet size in the aerosol generated with the Aeroneb nebulizer 
resulted in MSDS of 4.52±1.59 µm, confirming that most of the droplets were within 
the respirable range. These results are well aligned with previously reported values 
using the same system. 
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Table 4.1. Summary of the properties of the aerosols produced using different nozzles 
(FB240 and FB100) and under different experimental conditions, using pure water; Q 
liq: liquid flow rate; P air: air pressure; Q air: air flow rate; MSDS: mean droplet size 
distribution. 
Aerosol 
Producing 
Device 
Q liq 
(mL/min) 
P air 
(mbar) 
Q air 
(L/min) 
MSDS 
(µm) 
% droplets 
0.9< MSDS 
<5.25 
FB100 0.25 3000 0.67 3.00 61.15 
FB100 0.25 3500 0.82 2.00 66.8 
FB240 0.3 3000 1.57 2.43 64.28 
FB240 0.3 4500 1.6 3.28 71.11 
PennCentury 250 µL - - 23.33 2.61 
4.4.2. In vivo imaging experiments 
Evaluation of the dynamic images obtained after administration by endotracheal 
insufflation using the Penn-Century Aerosolizer showed progressive elimination of the 
radioactivity from the lungs. However, more than 85% of the starting radioactivity was 
still in the lungs after 10 minutes, suggesting slow clearance from this organ.  
PET images acquired immediately after administration of [18F]FDG using the three 
nebulisation methods showed different distribution patterns within the lungs (Figure 
4.5).  
When [18F]FDG was administered by endotraqueal insufflation using the Penn-Century 
Aerosolizer, the radioactive aerosol was not uniformly deposited in the whole lungs. 
Indeed, minute involuntary tilts of the microsprayer when administering the dose 
resulted in the deposition of the aerosol in only one lung, a phenomenon which could 
be observed even after mastering the technique (Figures 4.5a-4.5c).  Of note, even 
when the aerosol reached both lungs, the regional distribution was not uniform within 
the lungs, and the presence of hot spots and under-exposed regions could be observed 
by visual inspection of the images. Generally, the lower regions of the lungs received 
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systematically less amount of aerosol that the upper regions. Our results are in partial 
agreement with previous studies in which the regional distribution of TiO2 NPs in rat 
lungs was investigated after aerosol administration using the same system (13). In this 
previous work, the authors found low inter-animal variation in terms of dose deposited 
in the lungs, although the middle lobes were the regions which systematically received 
fewer doses. In our case, despite the high intra-individual variation and the high 
variability of the method, it was the lower regions of the lungs the ones which received 
fewer doses.  
Administration of the labelled aerosol using any of the two nebulisers resulted in a 
more uniform distribution of the aerosol within the whole lungs, as clearly seen by 
visual inspection of the images (see Figures 4.5d and 4.5e). The images were quantified 
to get precise data regarding the amount of radioactivity present in each of the lung 
lobes. With that aim, and using PMOD image analysis software, different spherical 
volumes of interest (VOIs) were drawn in the different regions of the lungs. The lungs 
were divided in six different regions (Figure 4.5f): left superior lobe (LS), left middle 
lobe (LM), left inferior lobe (LI), right superior lobe (RS), right middle lobe (RM) and 
right inferior lobe (RI), and VOIs were drawn in the different regions. Quantitative data 
(Figures 4.5g-4.5i) clearly show the lack of uniformity in the deposition of aerosol in 
the lungs when the Penn-Century Aerosolizer was used. Indeed, Figure 4.5g confirms 
that endotracheal insufflation results in non-uniform distribution of radioactivity, while 
the high standard deviation values reflect the high inter-subject variability. Contrarily, 
Figures 4.5h and 4.5i show that the relative concentration of radioactivity in the 
different lobes is similar, while small standard deviation values are obtained, 
confirming the low intra-subject variability. 
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Figure 4.5. (a-e) Representative coronal PET-CT rat images obtained immediately after 
administration of [18F]FDG by (a-c) endotraqueal insufflation using the Penn-Century 
Aerosolizer (3 different animals); (d) inhalation using the Ingeniatrics nebuliser; and (e) 
inhalation using the Aeroneb nebulizer; (f) VOIs drawn in the different regions of the 
lungs; (g-i) percentage of radioactivity in each VOI after administration using the Penn-
Century Aerosolizer (e), Aeroneb nebuliser (f) and Ingeniatrics nebuliser (g). LS: left 
superior; LM: left medium; LI: left inferior; RS: right superior; RM: right medium; RI: 
right medium; values in (g-i) are expressed as mean ± standard deviation, n=3. 
The PET images obtained in vivo were not used to determine the fraction of the dose 
deposited in the lungs, as these values could be more reliably obtained from ex vivo 
studies. In our case, image acquisition was not synchronised with the respiratory and 
cardiac cycles, and hence absolute quantification of the whole lung could be subjected 
to motion artefacts. Such artefacts can be neglected during quantification of the 
spherical VOIs, as these were strategically located within the region of the organ not 
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affected by lung and heart motion. Hence the determination of regional distribution is 
reliable. Indeed, our results are well aligned with previous works (6, 13), in which the 
authors reported a lack of uniformity within the lungs when the Penn-Century 
insufflators was used in mice. Such lack of uniformity need to be considered when e.g. 
therapeutic studies are conducted in the preclinical setting, as unexposed areas may 
remain undertreated while over-exposed regions may result in localised toxicological 
effects. 
4.4.3. Ex vivo imaging experiments 
Ex vivo imaging experiments were carried out to confirm the results obtained in vivo 
and to obtain more accurate information regarding the regional and local distribution 
of the [18F]FDG after administration. With that aim, immediately after finishing PET 
acquisition, animals were sacrificed, lungs were fixed with formalin and ex vivo PET-CT 
images were acquired. The advantage of ex vivo imaging with respect to in vivo 
imaging relies in two facts: (i) there are no motion artefacts due to animal respiration, 
and (ii) images can be acquired for long times; this is not the case of in vivo imaging, 
where the acquisition time is limited by the total time that the animals can remain 
under anaesthesia. Hence, higher resolution images can be expected from ex vivo 
imaging. Taking into account that >85% of the administered [18F]FDG remains in the 
lungs at t=10 min after administration and that the time gap between end of exposure 
and animal sacrifice was less than 10 seconds, we assumed that lung clearance during 
this time gap could be neglected.  
Visual inspection of the images showed similar results to those obtained in vivo, this is, 
uniform deposition within the lungs when the Ingeniatrics and the Aeroneb nebulisers 
were used (see Figures 4.6c for example of image) and low uniformity when the Penn-
Century Aerosolizer was used.    
The lungs were finally divided into different lobes and the amount of radioactivity was 
determined in a gamma counter (Figures 4.6d and 4.6e). Again, gamma counting 
results confirmed the results obtained in vivo. When [18F]FDG was administered using 
the Penn-Century Aerosolizer, the amount of radioactivity in the different lobes of the 
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lungs varied significantly. Additionally, high standard deviation values confirm the high 
inter-subject variability. When the radiotracer was administered by inhalation, the 
amount of radioactivity was homogenously distributed within the lungs. 
The results also confirmed that endotraqueal insufflation was the most efficient 
administration method, leading to almost quantitative deposition of the aerosol in the 
lungs (85±3%). Indeed, the rest of the radioactivity could be either absorbed on the 
walls of the syringe or in the trachea, the latter being contaminated during 
introduction or withdrawal of the delivery needle.  
 
 
Figure 4.6. (a) Photograph of the harvested, fixed lungs of a rat after exposure to 
inhalation of [18F]FDG using the Aeroneb nebuliser; (b) Coronal CT image of the 
harvested lungs; (c) coronal PET-CT ex vivo image of the harvested lungs; (d) schematic 
illustration of the different  lung lobes; (e) relative concentration of radioactivity in 
each lobe after endotraqueal insufflation using the Penn-Century Aerosolizer (black 
bars), inhalation using Ingeniatric nebuliser (white bars), and inhalation using Aeroneb 
nebuliser (grey bars).  
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On the contrary, both aerosol inhalation systems resulted in poor deposition 
efficiency. Indeed, only 0.07±0.01 and 0.08±0.02 of the aerosolised dose reached the 
lungs when Ingeniatrics or Aeroneb nebulisers were used. The low dose deposited in 
the lungs using the Ingeniatrics nebulizer is due to a combination of factors, mainly: 1) 
The tidal volume of Sprague Dawley rats is around 0.29 mL/100g in resting conditions 
(14). Considering that under our anaesthetic conditions rats maintained an average 
breathing frequency of 60 breaths/minute, the inhaled air volume for each rat was 
estimated to be around 39 mL/min for a rat weight of 225g. Taking into account that in 
our first trials with the FB240 nebuliser the air flow rate was set to 1.6 L/min (required 
for a proper generation of the aerosol) a simple mass balance provides a maximum 
inhaled fraction of 2.4% of the total aerosol, assuming that tidal volume is not 
significantly affected by the anaesthesia. With the aim of increasing the inhalable 
fraction, Ingeniatrics developed a new nozzle (FB100) that could work at lower air flow 
rates (0.6 L/min). Unfortunately, the fraction of the dose actually deposited in the 
lungs was equivalent to that obtained with the FB240 nozzle.   
Additionally to the mass balance issue, a severe condensation of the aerosol in the 
main chamber could be observed during nebulisation. The fraction of the aerosol 
condensed was estimated by recovering the condensed fraction and measuring the 
amount of radioactivity. The results showed that approximately 75% of the nebulised 
solution was indeed condensed in the walls of the chamber, and hence was not 
available to be breathed by the animals. Altogether, these results confirm that the 
maximal theoretical inhalable fraction per animal is close to 0.6%.  
Aiming at minimising condensation and to mitigate also mass balance effects, a new 
device that enabled non-continuous nebulisation was implemented by Ingeniatrics. 
Different nebulisation experiments were carried out using the ON/OFF control system. 
In all experiments, the total exposure time was exactly the same (10 minutes) but the 
time the nebulizer was switched on was modified according to the ON/OFF pattern. 
Unluckily, continuous and non-continuous nebulisations resulted in equivalent 
deposition efficiency, which was in all cases very close to 0.1%.    
Chapter 4. Pulmonary administration methods 
 
63 
 
For the Aeroneb nebuliser, the inhaled fraction was similar to that obtained for the 
Ingeniatrics nebuliser, despite in this case the air flow was set to 100 mL/min and 
hence higher dose in the lungs could be expected. The low values obtained might be 
due to severe condensation, which was observed although in this case could not be 
measured due to the difficulties in recovering the condensed fraction.    
Altogether, our results suggest that the administration tool used for the delivery of 
aerosols in the pre-clinical setting has a huge impact both in the dose deposited in the 
lungs and in the regional distribution within the lungs. This fact, which has been widely 
explored in the clinical setting using nuclear imaging techniques (15-17), has remained 
mostly unexplored in the pre-clinical setting. Taking into account that preclinical 
studies always precede clinical trials, our results suggest that studies to investigate 
both parameters should be routinely conducted for a proper interpretation of the 
results. 
The results obtained in the experiments described above have a significant impact on 
the planning of potential preclinical therapeutic studies using aerosolized drugs. 
Indeed, the main aim of this work was to provide a recommendation about the 
nebulisation system to be used in future therapeutic experiments to be conducted at 
Erasmus Medical Centre (Rotterdam) using an infection rat model and aerosolized 
antimicrobial peptides encapsulated in/attached to nanocarriers. Based on our results, 
it was clear that with the Penn-Century Microsprayer most of the drug should be 
deposited in the lungs, thus reducing the amount of drug required to achieve a certain 
concentration in the lungs. However, the uniformity of the deposition is questionable 
and may depend on the operator and uncontrolled experimental factors. On the other 
hand, the use of the nebulisation systems results in a uniform distribution, but the 
amount of drug deposited in the lungs is very low, and hence huge amounts of drug 
would be required to achieve a predefined drug concentration in the lungs.  
The distribution of an inhaled drug within the lung clearly influences the effectiveness 
of that treatment, and a viable treatment may become ineffective if the drug is not 
delivered in a sufficient concentration to the infected areas within the lung. 
Considering these facts, our recommendation was to use one of the nebulisation 
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systems in order to ensure that the whole lung was treated. However, due to the low 
fraction of the dose deposited in the lungs and the large number of animals to be 
included in therapeutic experiments, the amount of nanomedicine required to conduct 
the experiments was too large and could not be produced. Because of this, the Penn-
Century Microsprayer was selected as the preferred alternative, at the risk of having a 
high variability in the regional concentration of the drug in the lungs of the infected 
animals.     
4.5 Summary and Conclusions 
The work reported in this chapter shows that Positron Emission Tomography is a very 
useful tool for the evaluation of the regional distribution of aerosols in the lungs. In 
our case, radiolabelling of the aerosol using [18F]FDG enabled the investigation of the 
regional distribution within the lungs, while dissection and gamma counting enabled 
the determination of the fraction of the dose actually deposited in the lungs after 
administration using endotracheal insufflation and two different nebulisers. While 
endotracheal insufflations resulted in ca. 85% of the aerosols reaching the lungs, 
uniform distribution could not be achieved, most of the dose being deposited in the 
upper lobes and with high inter-subject variability. Nebulisation using the two different 
nebulizers resulted in a homogeneous distribution within the lungs, although only 
<0.1% of the aerosol was actually deposited in the lungs. Both the fraction of the 
aerosol reaching the lungs and the regional distribution may have a huge impact in 
putative therapeutic or toxicological studies. Hence, our results confirm that a 
thoroughly investigation of aerosol generators is of paramount relevance in the pre-
clinical context, and that nuclear imaging techniques may offer a valid alternative. 
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Chapter 5. Evaluation of the pharmacokinetic properties of 
novel nanoparticle-based antibiotics after lung administration 
using Positron Emission Tomography 
5.1. Introduction 
Nanotherapies based on controlled delivery of drugs entrapped into or attached to 
nanocarriers (NCs) have emerged as a promising alternative to improve the 
therapeutic index of drugs by increasing their targeting capacity and accumulation in 
specific organs, tissues or cells while decreasing potential toxic and off-target side 
effects. Different nanocarriers are currently used in the clinical field to improve 
accumulation of drugs in tumours. For example, DaunoXome and Doxil are liposome-
based drugs that are nowadays used to treat Kaposi’s sarcoma (1, 2) as well as ovarian 
and breast cancer (1-3). Similarly, micelle-based drugs containing doxorubicin, 
paclitaxel, or cisplatin are in various stages of clinical trials (4-6). Polymer-based drugs 
have also experienced similar clinical success; Zoladex and Lupron Depot are small 
polymer rods and polymer microspheres, respectively. Both can successfully entrap 
Luteinizing hormone-releasing hormone (LHRH) analogues and are clinically used to 
treat prostate cancer (7).  
The effective transition of novel nanomedicines into the clinical arena demands for a 
proper assessment of their pharmacokinetic properties. Additionally, as described in 
the previous chapter, the relationship between the administered dose and the amount 
of drug deposited in the treated organ, the regional distribution of the nanomedicines 
in the target organ or tissue and the residence time and/or clearance to the circulatory 
system need to be assessed for proper therapy planning. For conventional drugs, the 
pharmacokinetic information can be obtained in pre-clinical tests through classical 
approaches, e.g. by analysis of biological samples (tissues, fluids) using a combination 
of techniques such as high performance liquid chromatography (HPLC) and mass 
spectrometry (MS). In the particular case of nanomedicines, the same approaches can 
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be utilised to assess the distribution of the entrapped/attached drug. However, 
tracking the nanocarrier is more challenging, because these are extremely difficult to 
detect and quantify once distributed in an organism.  
One alternative to complement classical approaches at the pre-clinical level consists of 
radiolabelling the NC, the drug, or both using positron or gamma emitters. Hence, 
after the administration of the radiolabelled nanomedicines, images at different time 
points can be acquired in order to determine the regional distribution of the labelled 
entities at the whole body level at different time points, providing full pharmacokinetic 
data while minimizing the number of experimental animals (8). This information 
concerns not only to the targeted organ; because whole body images can be acquired, 
information about translocation to remote organs or elimination routes can be 
obtained. Also, blood samples can be withdrawn during image acquisition, providing 
information about translocation of the labelled species to the blood stream. 
Importantly, the techniques are fully translational to the clinical setting. In other 
words, the same experimental techniques used in the preclinical scenario can be 
applied to humans, because nuclear imaging techniques are minimally invasive and 
only require the administration of a sub-pharmacological amount of the substance 
under investigation.  
As mentioned in chapter 2, the work conducted in the current PhD project is framed in 
the context of the EU-funded project PneumoNP, aiming at developing new 
pulmonary-administered nanodrugs to combat antibiotic resistant lung infections. 
When the lung is the target organ, the use of nuclear imaging modalities faces some 
difficulties which need to be overcome. One of the main drawbacks to achieve 
accurate quantification in vivo is the breathing-related motion of the subject during 
image acquisition. Such movement hampers accurate location of the radioactive signal 
and hence compromises quantification, especially when small animals are 
investigated. Of note, gated imaging can be applied to correct for this; alternatively, in 
the preclinical setting, excision of the organs of interest and ex vivo imaging can 
mitigate this problem, at the cost of animal sacrifice. Additionally, resolution of nuclear 
imaging is usually poor (around 1 mm in the centre of the field of view for preclinical 
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systems, close to 5 mm for clinical systems). If higher resolution images are required, 
tissue dissection, slicing and evaluation using autoradiography can provide accurate 
information about regional distribution of the administered drug with a resolution 
close to 50 µm. Imaging studies can be combined with dissection and gamma counting 
to get more accurate quantitative information about the actual amount of radioactivity 
accumulated in the different organs.  
In the frame of the PneumoNP project, all the above mentioned techniques (in vivo 
imaging, ex vivo imaging, dissection and gamma counting) have been used and 
combined in order to evaluate the pharmacokinetic properties of two novel 
antimicrobial peptides (AMPs) developed by partners Adenium Biotech (Denmark) and 
SetLance (Italy), that have shown activity against Klebsiella pnemoniae, a multidrug 
resistant (MDR) Gram-negative bacteria (9, 10); These antibacterial drugs have a 
positive net charge that allows them to interact selectively with anionic bacterial 
membranes and with other negatively charged structures, such us lipopolysaccharide 
(LPS), lipoteichoic acid (LTA) and DNA. Their mechanism of action is normally through 
specific binding to bacterial surfaces, by which they provoke cell penetration and in 
some cases inhibition of metabolic pathways.  
Both AMPs (identified as AA139 and M33) were modified by the corresponding 
partners by incorporating one tyrosine residue to enable subsequent labelling with a 
positron emitter. In this work, radiolabelling was achieved by aromatic iodination using 
Iodine-124 (positron emitter with a half-life of 4.18 days). The labelled peptides were 
then administered to wild type (WT) rats by endotracheal insufflation. The 
pharmacokinetic properties and the residence time of the AMPs in the lungs were 
assessed in two different scenarios: a) when they were administered in their “free” 
form and b) conjugated with polymeric NPs or with lipid-core micelles (MC) acting as 
the nanocarriers. Moreover, the residence time in the lungs of “empty” polymeric NP 
and its parent polymer was also evaluated (Figure 5.1).   
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Figure 5.1. Summary of all the radiolabelled species that were evaluated by imaging 
studies after endotracheal insufflation. 1: AMPs (AA139 and M33); 2: Polymeric NPs 
(empty nanocarrier); 3: polymer; 4: AMPs-PNPs nanosystems (AA139-PNPs and M33-
PNPs); 5: AMPs-MCs nanosystems (AA139-MCs and M33-MCs).   
5.2. Objectives 
The specific objectives of this work are: 
1. To develop labelling strategies for the incorporation of positron emitters in the 
selected antimicrobial peptides.  
2. To determine the residence time in the lungs of radiolabelled antimicrobial 
peptides, either administered as “free peptides” or combined with selected 
nanocarriers, after aerosol administration.    
3. To develop labelling strategies for the incorporation of gamma emitters in 
selected nanocarriers. 
4. To evaluate the residence time in the lungs of the selected nanocarriers after 
aerosol administration.  
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5.3. Experimental Part 
5.3.1 General remarks 
The AMPs were provided by partners Adenium Biotech (Denmark) and SetLance (Italy), 
while polymeric NPs and the parent polymer were provided by partner CIDETEC. 
Hence, the preparation of these AMPs and carriers is not described in this PhD thesis. 
The technology for the preparation of the micelles was developed by partner UU (The 
Netherlands) and transferred to CIC biomaGUNE, because the incorporation of the 
radiolabelled AMP required in situ preparation of the nanosystems. For this particular 
case, a brief description of the preparation protocol will be included in the 
corresponding section.  
5.3.2 Radiolabelling 
5.3.2.1. Radiolabelling of polymeric nanoparticles (PNPs) and parent polymer 
Gallium-67 (67Ga) was obtained from Mallinckrodt Medical, B.V. (Le Petten, The 
Netherlands) as a citrate salt. Prior to radiolabelling reactions, 67Ga citrate was 
converted into 67Ga chloride using a modified procedure reported previously (11). In 
brief, the 67Ga citrate solution was first eluted through two silica cartridges connected 
in series (Sep-Pak® Silica Plus Light, Waters Co., Milford, MA, USA) at a constant flow 
rate of 0.1 mL/min. The cartridges were dried with air for 1 minute and washed with 
ultrapure water (5 mL, obtained from a Milli-Q® Purification System, Millipore®, Merck 
KGaA, Darmstadt, Germany). Desorption of 67Ga ions was finally achieved by elution 
with 0.1 M aqueous HCl solution (1 ml) at a flow rate of 0.1 ml/min. The eluate was 
collected in different fractions (ca. 100 µL each) and those fractions containing the 
maximum activity concentration (typically fractions 4-5) were used in subsequent 
labelling experiments.  
Radiolabelling of PNPs and parent polymer was performed by incubation of the NODA-
functionalized nanoparticles (PNP-F-NODA) or linear polymer with 67GaCl3. In a typical 
experiment, 50 µL of PNPs or polymer solution (1 mg/mL) and 50 µL of 67GaCl3 (ca. 37 
MBq) were incubated in sodium acetate buffer solution (0.2M, pH = 4.2, 200 µL) at 
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25°C for 45 min. After incubation, the crude material was purified by centrifugal 
filtration using Millipore Amicon® Ultra filters (3 kDa cut-off). The resulting precipitate 
was washed three times with sodium acetate buffered solution to remove unreacted 
67Ga species and the amount of radioactivity in the pellet, the supernatant, and the 
washings was determined by a dose calibrator (CPCRC-25R, Capintec Inc., NJ, USA). 
Labelling efficiency (expressed in percentage) was calculated as the ratio between the 
amount of radioactivity in the filter and the total amount of radioactivity in all 
fractions. Finally, the nanoparticles or polymer were suspended in 0.2 M sodium 
acetate buffer solution (pH 4.2). Radiochemical yield was calculated as the ratio 
between the amount of radioactivity in the resuspended fraction and the starting 
amount of radioactivity. 
5.3.2.2. Radiochemical stability of PNPs and parent polymer 
Radiolabelled entities prepared as described above were incubated in sodium acetate 
buffered solution at 37 °C using a digital block heater. At different time points (1, 3, 24, 
48, 72 and 144 hours) samples were withdrawn and the amount of radioactivity was 
measured. The 67Ga-radiolabelled PNPs and polymer were filtered, washed twice with 
ultrapure water, and the amount of radioactivity in the filter and the filtrate/washings 
was measured. The radiochemical stability was calculated as the percentage of 
radioactivity in the pellet with respect to the total amount of radioactivity (pellet + 
filtrate + washings). 
5.3.2.3. Radiolabelling of AMPs 
Experiments were conducted with peptides M33 (provided by partner SetLance) and 
AA139 (provided by Adenium Biotech). The radio-iodination of the peptides was 
carried out by electrophilic aromatic substitution on the tyrosine residues. With that 
aim, a solution of the peptide (50 µg/50 μL) was incubated with Na[124I]I in 0.2 M 
sodium acetate buffer solution (50 µL, pH 5.5) for 2 hours at 25°C in the presence of 
Iodobeads®. In case of AA139 peptide, the crude reaction was purified by retention in 
a C-18 cartridge (Sep-Pak® Light, Waters) and subsequent elution using 0.1% aqueous 
TFA solution/methanol 20/80 (1 mL). The solvent was evaporated and the residue 
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reconstituted with 0.2 M sodium acetate buffer solution (300 µL, pH 5.5). The peptide 
M33 was purified by size exclusion chromatography (SEC) using Illustra™ Nap™-5 
Sephadex™ columns G-25 DNA grade (GE Healthcare, USA) columns, preconditioned 
with a sodium buffer solution (10 mL, 0.02 M, pH=5.5). In both cases, chemical and 
radiochemical purity were determined by radio-HPLC, using a Mediterranean Sea 18 
column (4.6 x 150 mm, 5 μm) as the stationary phase and 0.1% solution of TFA in 
water (A) and pure methanol (B) as the mobile phase. The following gradient was used 
for the M33 peptide; initial: A-60% B-40%; 4 min: A-60% B-40%; 14 min: A-20% B-80%; 
18 min: A-60% B-40%; 20 min: A-60% B-40%. Injected volume was 20 µl. The gradient 
used for the  AA139 peptide was as follows; initial: A-90% B-10%; 4 min: A-85% B-15%; 
6 min: A-75% B-25%; 10 min: A-75% B-25%: 16 min: A-5% B-95%; 18 min: A-5% B-95%; 
20 min: A-90% B-10%; 22 min: A-90% B-10%. 
Radiochemical stability of the labelled AMPs was assessed by incubation in different 
media at 37°C. At different time points, samples were withdrawn and analysed by 
HPLC using the experimental conditions described above. Radiochemical stability was 
directly calculated from chromatographic profiles.    
5.3.2.4. Preparation of AMP-NP conjugates 
Preparation of two different AMP-NP conjugates or nanosystems (NSs) was carried out 
by combining previously radiolabelled AA139 or M33 peptides (following the 
procedure described above) with either PNPs provided by CIDETEC or lipid-core 
micelles prepared in situ. The protocols to efficiently attach or encapsulate AMPs 
to/into different NCs were developed by partners CIDETEC (AMP-PNPs) and University 
of Utrecht (AMP-micelle) and then transferred to our laboratory. These protocols are 
briefly described below. 
Combination of AMPs and PNPs 
Partner CIDETEC optimised a protocol to efficiently load AMPs to PNPs. At 
physiological pH these NCs, which have carboxylic acid groups attached on their 
surface, are in fact negatively charged and thus it is possible to combine them with 
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positively charged AMPs (AA139 and M33) by electrostatic interactions (Figure 5.2.). 
During optimization of the experimental protocol, different concentrations of peptides 
were added to water-based dispersion of nanoparticles to determine the limit of 
loading in terms of stability and maximum peptide content in the NSs. After 
incubation, the solutions were purified by filter centrifugation using Millipore Amicon® 
Ultra filters (5000 MWCO) and the presence/absence of peptide in the filter and 
filtrate was assessed by UV-Vis. Moreover, the incorporation of AMPs to PNPs was 
confirmed by Dynamic Light Scattering (DLS) and Z-potential (Z-pot) measurements. 
The hydrodynamic radius of the nanoparticles and NSs was measured on a Zetasizer 
Nano ZS, ZEN3600 Model (Malvern Instruments Ltd) by Dynamic Light Scattering 
(NIBS®) technique. The scattering angle was fixed at 90°. A filtered (0.22µm) water 
dispersion of the nanoparticles at a concentration of 0.3 mg/mL was used and the 
experiments were performed at 25 °C in triplicate. The Z-pot measurements were also 
performed by using this instrument at a concentration of 1 mg/mL in 1mM NaCl 
solution without 0.22 µm filtration. 
 
Figure 5.2. Electrostatic coupling of AMPs to PNPs. 
Attachment of radiolabelled peptides to the polymeric NPs was carried out following 
the exact instructions provided by CIDETEC. In brief, the corresponding amount of 
labelled peptide (124I-labelled AA139 or M33, 50 µg/300 μL) was incubated with 
polymeric NPs (500 µg/500 μL) at 25 °C for 15 hours. Then, the crude of reaction was 
purified by centrifugal filtration using Millipore Amicon® Ultra filters (5000 MWCO) to 
eliminate the unbound peptide.  
Combination of AMPs and micelles 
In a similar manner, partner Utrecht University investigated the maximum peptide and 
lipid (DSPE-PEG2000) concentration required for efficient encapsulation. A DSPE-PEG2000 
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lipid film was hydrated (see Figure 5.3) with different concentrations of peptides in PBS 
(10 mM, 0.8% NaCl, pH 7.4), and the excess of free peptide was removed from micelles 
by dialysis. Finally, the peptide concentration was determined by UPLC.  
 
Figure 5.3 Formation of AMP-micelle nanosystems by peptide encapsulation. 
Bearing in mind that in our case peptides were radiolabelled with Iodine-124 (t1/2=4.18 
days) and that dialysis requires long time of incubation, a faster method for NS 
purification was employed (Figure 5.4). In fact, purification was achieved by size 
exclusion chromatography (SEC), using Illustra™ Nap™-5 Sephadex™ G-25 DNA grade 
columns (GE Healthcare, USA), preconditioned with ultrapure water (18MΩcm). The 
eluted product was collected in 100 µL fractions and those containing the highest 
concentration of radioactivity (usually in the initial fractions) were diluted with physical 
saline solution and used for in vivo experiments (vide infra). Incorporation ratios were 
calculated as the ratio between the amount of radioactivity present in the NC-AMP 
conjugates and the starting amount of labelled AMP.  
 
Figure 5.4. Formation of radiolabelled AMP-micelle nanosystems by encapsulation of 
[124I]AMPs within micelles. 
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5.3.3 Animal Experiments 
5.3.3.1. General considerations 
All animal experiments were performed in accordance with the Spanish policy for 
animal protection (RD53/2013), which meets the requirements of the European Union 
directive 2010/63/UE regarding the protection of animals used in experimental 
procedures. The procedures were approved by the Ethical Committee of CIC 
biomaGUNE and authorized by the regional government. 
5.3.3.2. Administration of the radiolabelled NCs, AMPs and AMP-NC conjugates 
Female Sprague Dawley rats (Janvier, Le Genest-Saint-Isle, France) were used. Rats 
were anesthetized with 3-5% isoflurane (IsoFlo®, Abbott Laboratories) in pure O2 for 5 
minutes to ensure deep sedation. Once animals were under sedation, radiolabelled 
entities were administered by endotracheal insufflation using a Penn-Century 
MicroSprayer® Aerosolizer (FMJ-250 High Pressure Syringe Model, Penn-Century. Inc. 
Wyndmoor, USA). A small animal Laryngoscope (Model LS-2, Penn-Century. Inc.) was 
used for correct visualization of the epiglottis, ensuring a correct positioning of the tip 
just above the carina. A pre-defined volume of radiolabelled solutions (50 µL, 
established by using spacers in the syringe plunger) was administered (amount of 
radioactivity around 1.85 MBq). Immediately after, rats were submitted to in vivo 
imaging studies (see below). Rats administered with 67Ga citrate solution or [124I]NaI in 
saline solution were used as controls. 
5.3.3.3. In vivo imaging experiments of selected NCs: PNPs and its corresponding 
parent polymer 
Immediately after administration of either the radiolabeled PNPs or the parent 
polymer, and without recovering from sedation, animals were positioned in an eXplore 
speCZT CT preclinical imaging system (GE Healthcare, USA) to perform in vivo studies. 
Body temperature was maintained with a homeothermic blanket control unit (Bruker 
BioSpin GmbH, Karlsruhe, Germany) to prevent hypothermia, and a SPECT scan was 
acquired for 30 minutes. Animals were then recovered from sedation and returned to 
their cages. Imaging sessions were repeated at t = 24, 48 and 72 hours after 
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administration. In these cases, anaesthesia was induced by inhalation of 3-5% 
isoflurane (IsoFlo®, Abbott Laboratories) in pure O2 as the carrier, and maintained 
using 1% - 2% isoflurane during image acquisition. After each SPECT scan, a CT 
acquisition was performed to provide anatomical information of each animal and 
enable unequivocal localization of the radioactive signal.   
The SPECT images were reconstructed using a ordered-subset expectation 
maximization (OSEM) iterative algorithm (3 iterations/3 subsets, 128 x 128 x 32 array 
with a voxel size of 0.55 x 0.55 x 2.46 mm3), whereas for the CT a cone beam filtered 
back-projection a Feldkamp algorithm (437 x 437 x 993 array with a voxel size of 
0.2 x 0.2 x 0.2 mm3) was used. After reconstruction, images were quantified using 
πMOD analysis software (version 3.4, PMOD Technologies Ltd.). Volumes of interest 
(VOIs) were manually drawn in different regions of the lungs on the CT images and 
translated to the SPECT images. The relative concentration of radioactivity in the 
different VOIs was finally determined. 
5.3.3.4. In vivo imaging experiments of selected AMPs and NSs 
Following a similar procedure to that followed for the in vivo evaluation of NCs, PET-CT 
imaging studies were carried out to investigate the residence time in the lungs of 
selected AMPs, both in their free form and as a part of the NSs. With that aim, 
immediately after administration of the radiolabelled species and without recovering 
from sedation, animals (n=4 per compound) were placed in an eXploreVista-CT small 
animal PET-CT preclinical imaging system (GE Healthcare, USA) to perform in vivo 
studies. Animals were then recovered from sedation and returned to their cages. 
Imaging sessions were repeated at t = 3, 6, 9, 15 and 24 hours after administration. 
After image reconstruction using filtered back projection reconstruction algorithm, 
images were quantified using πMOD software. Volumes of interest (VOIs) were 
manually drawn in the lungs on the CT images and translated to the PET images. Since 
absolute quantification is possible in PET, the exact amount of radioactivity in the 
different VOIs was assessed at all time-points for all the different species and the 
values were used to determine residence time of the labelled species in the lungs. 
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5.3.3.5. Ex vivo experiments of selected NCs: PNPs and parent polymer 
Since absolute quantification in SPECT-CT is extremely challenging, ex vivo experiments 
were also carried out to confirm the results obtained in vivo. With that aim, at pre-
defined time points after administration of the labelled species (t=0, 72 and 144 hours) 
animals were sacrificed by exsanguination followed by perfusion with saline solution. 
The lungs were harvested, dissected into different lobes and the amount of 
radioactivity in each lobe and the trachea was accurately determined by gamma 
counting (WIZARD2 Gamma Counter, Perkin Elmer, Waltham, USA). 
5.4. Results and discussion 
5.4.1. Radiolabelling 
5.4.1.1. Radiolabelling of polymer nanoparticles (PNPs) and the corresponding parent 
polymer 
Radiolabelling of PNPs and parent polymer was approached by formation of a 
radiometal-chelator complex. Under optimized experimental conditions (T = 25°C, t = 
45 min, pH = 4.2), radiochemical yields of 51%±5% and 84%±4% (non-decay corrected) 
could be achieved for PNPs and its corresponding linear parent polymer (respectively).  
The labelling strategy followed for the incorporation of 67Ga into PNPs and the 
corresponding linear parent polymer, based on the formation of a chelator-67Ga 
complex, has been previously described in the literature and applied to the 
radiolabelling of small peptides and also NPs. In the context of NPs, one of the first 
examples found in the literature was reported by Hwang et al (12), who prepared 
cobalt–ferrite nanoparticles surrounded by fluorescent rhodamine within a silica shell 
matrix and functionalized with an aptamer targeting nucleolin, a cellular membrane 
protein highly expressed in cancer. The resulting particles were further decorated with 
a bifunctional chelator containing NOTA and labelled with 67Ga. The authors reported a 
labelling efficiency of 40% as measured by quantitative TLC analysis and good stability 
of the labelled particles in mouse serum. In our case, slightly superior labelling 
efficiencies were achieved. Noteworthy, such labelling efficiency could be increased by 
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just increasing the amount of NPs to be incubated with the radionuclide. However, this 
was considered as unnecessary and, to a certain extent, not convenient, due to two 
main reasons: First, the labelling efficiency for both the PNPs and the parent polymer 
was sufficient to approach in vivo studies in rodents. Second, it has to be noted that 
the purification method employed cannot separate the labelled PNPs (or polymer) 
from the unlabelled analogues. Hence, increasing the amount of PNPs or polymer 
leads to a significant decrease in the final molar activity, which ultimately results in a 
higher mass dose injected into the animal. In our case, the experimental conditions 
ensured an injected dose <50 µg to the animal, which produced no apparent side or 
toxicological effects on the animals. 
Stability studies of the radiolabelled PNPs and parent polymer were performed by 
incubation in buffered saline solution. Ideally, the stability of the labelled species 
should be determined in vivo. Indeed, the determination of the stability of the labelled 
species is paramount because detachment of the radionuclide may have a significant 
impact on the conclusions obtained from imaging studies. In the context of small 
molecules or even macromolecules such as proteins or antibodies which are 
administered intravenously, such information can be obtained by administration of the 
species under investigation followed by blood sampling, isolation of the plasma and 
further analysis. However, this strategy is difficult to apply in the case of NPs, mainly 
due to the fact that NPs are not easily isolated from biological samples. Because of 
this, alternative strategies have been reported, being the most commonly used the 
incubation of NPs in fluids that mimic the in vivo environment such as water, buffers, 
saline, serum, plasma or solutions containing amino acids, proteins or complexing 
agents. Typically, the radiochemical stability of NPs labelled using the formation of a 
chelator-radiometal complex and aimed to be intravenously administered, is 
investigated by incubation in a solution of a complexing agent such as DTPA (13), as 
this can act as a sequestrator of the radiometal, mimicking thus the presence of 
complexing proteins present in blood. In our case, because the labelled PNPs or 
polymers were administered by endotracheal insufflation, in vitro stability studies in a 
buffered solution were anticipated as sufficient to predict the stability of the radiolabel 
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in vivo. Of note, in vivo control experiments were performed with “free gallium” to 
ensure that the distribution pattern observed after the administration of 67Ga-PNPs or 
polymer was not significantly affected by the detachment of the label (vide infra).      
5.4.1.2. Radiolabelling of AMPs 
Radiolabelling of peptides can be achieved by following mainly three different 
strategies: Radioiodination, radiofluorination and radiometallation.   
Radioiodination is probably the most widely used strategy and can be achieved 
following three different methods: The easiest one is the incorporation of the 
radioiodine by in situ oxidation of the anionic species (I-) using an oxidizing agent in 
solution, e.g. chloramine-T (14), and subsequent electrophilic substitution in the 
aromatic ring of tyrosine residues. This methodology provides high incorporation 
yields, although it cannot be always applied because not all peptides contain tyrosine 
residues. The main drawback of this strategy is that is very unspecific, because no 
control exists on the position in which the iodine atom is incorporated, the product 
mixture obtained is often complex and requires extensive HPLC purification (15). 
Additionally, the strong oxidizing character of chloramine-T can lead to the oxidation 
of sensitive amino acids. This side effect can be mitigated by using milder oxidants 
such as Iodogen (16), which is currently commercially available. Alternatively to direct 
radioiodination, indirect methods consisting of the covalent attachment of a pre-
labelled group to one lysine residue have been developed; the most widely used 
conjugation reagent is radioiodinated N-succinimidyl 3-(4-hydroxyphenyl)propionate 
(Bolton-Hunter reagent) (17). By following this approach, multiple products can be 
formed by the reaction with the chain end and/or a variety of side chains and usually 
time-consuming purification methods are required when single species are to be 
isolated. Finally, if the peptide under investigation already contains a iodine atom, 
isotopic exchange can be conducted (18). A summary of these three strategies is 
summarised in Figure 5.5. 
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Figure 5.5. Different strategies for the radioiodination of peptides: a) electrophilic 
substitution in the aromatic ring of tyrosine residues; b) isotopic exchange and c) 
indirect radioiodination by covalently binding a pre-labelled group (Bolton-Hunter 
reagent) to lysine residues. 
 
In our case, both peptides M33 and AA139 were designed to contain a tyrosine residue 
in a non-active region of the peptide sequence, and hence the direct radioiodination 
was anticipated as the easiest and more efficient methodology. Indeed, by following 
direct radioiodination in the presence of the oxidizing agent resulted in overall decay-
corrected radiochemical yields after purification of 36±9% and 62±2%, respectively, 
when 124I was used. Molar activities in both cases were in the range 0.5-1.5 GBq/µmol 
at the end of the synthesis. Both the radiochemical yield and the molar activity were 
appropriate to approach further steps, either direct in vivo investigation or attachment 
to/entrapment into the NCs.  
It is worth mentioning that stability studies for M33 by incubation in saline solution 
showed that 20% of the parent peptide was degraded after 1 hour, and this value 
increased up to 60% at t=48 hours. However, the labelled peptide showed much higher 
stability in 0.1% TFA in water/methanol (20/80). In this media, more than 95% of the 
parent peptide remained unchanged during 48 hours (Figure 5.6, left), and hence this 
media was selected to store the labelled peptide until further use. The peptide AA-139 
showed good stability in sodium acetate buffer, pH=5.5; see Fig. 5.6, right), with 
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almost all the radioactivity accounting for the labelled peptide even after 2 days of 
incubation.
 
Figure 5.6 Left: Stability of 124I-labelled M33 as determined by HPLC in different media; 
Media A: PBS 0.02M, pH=7.4; media B: 0.1 % solution of TFA in water/methanol 
(20/80); right: Stability of 124I-labeled AA-139 as determined by HPLC in sodium acetate 
buffer at pH = 5.5. Results are expressed as percentage of unchanged labelled peptide 
as mean ± standard deviation, n=3.   
5.4.1.3. Preparation of AMP-NP conjugates 
As already stated in the introduction of this chapter, we can find many examples of 
nanomedicines (combinations of drugs and nanoparticles) that are already being used 
in the clinics, and others that are in advanced clinical stages. These nanoformulations 
can be prepared by mainly three different strategies: encapsulation, covalent and non-
covalent binding. Indeed, the biological fate of the drug will vary depending on how 
the drug is attached to the NC. In this regard, we can find different studies in the 
literature. For example, Kim S.W. et al identified that covalently conjugated, non-
covalent polyethylene glycol coated and encapsulated nanodrugs selectively 
influenced drug uptake and the intracellular and extracellular trafficking of cancer cells 
(19).  They prepared three different types of nanodrugs to investigate their effect on 
intracellular dynamics. More precisely, encapsulated-doxorubicin (DOXOVES®), PEG-
coated-DOX (non-covalently bound to carbon nanotubes) and covalently conjugated 
DOX (using amide bonds with carbon nanotubes) were used in the study. All the 
nanoformulations exhibited high drug stability (less than 20% drug release until 288 
hours) under extracellular physiological conditions (PBS, pH 7.2). In contrast, under 
intracellular-like conditions (acidic pH and in presence of active enzymes) PEG coated 
0
20
40
60
80
100
120
0 20 40 60
%
 U
n
ch
an
ge
d
 p
e
p
ti
d
e
Time / hours
M33-PEG
Media A
Media B
0
20
40
60
80
100
120
0 20 40 60
%
 U
n
ch
an
ge
d
 p
e
p
ti
d
e
Time / hours
M33
Media A
Media B
0
20
40
60
80
100
120
0 10 20 30 40 50 60
%
 U
n
ch
an
ge
d
 p
ep
ti
d
e
Time / hours
AA-139
Chapter 5. Evaluation of novel NP-based antibiotics 
 
83 
 
drugs were abruptly released (nearly 100% of the drugs) from the carbon nanotubes 
after 2 hours of incubation. On the other hand, both covalent conjugation and 
liposomal encapsulation exhibited relatively stable drug release (i.e. less than 50% until 
288 hours). Regarding nanodrug uptake in cancer cells, authors observed greater 
uptake in covalently conjugated doxorubicin than liposomal encapsulated or PEG 
coated.  
As explained above, in our project the strategies that were followed to incorporate the 
AMPs to different nanocarriers were by electrostatic interactions (combination of 
AMPs and PNPs) and by encapsulation (combination of AMPs and micelles). 
Combination of AMPs and PNPs 
Electrostatic interactions have been indicated as one of the potentially important 
physical forces involved in competitive binding. In this way, many peptides and 
proteins have been attached to NPs following this strategy. For example, Hildebrandt 
et al. prepared superparamagnetic iron-oxide nanoparticles (SPIO) coated with dextran 
and functionalized with peptides by electrostatic interactions (20). Small peptides 
containing a specific recognition sequence and amino acids that were positively 
charged under physiological conditions were bound to the negatively charged surface 
of a modified dextran. The binding was estimated by size distribution and fluorescence 
measurements (peptides contained a fluorescent dye). Similarly, Wang et al. also 
investigated the contribution of electrostatic interactions to protein-AuNP binding by 
studying the pH-dependent binding behavior of two proteins, GB3 and ubiquitin (21). 
When pH was increased from pH 5 to pH 8.3 and the net charge of proteins went from 
positive to neutral, both proteins exhibited a decrease in adsorption capacity.  
In our case, we also decided to follow this strategy to bind the AMPs to polymeric NPs 
by electrostatic interactions. According to the results obtained by CIDETEC, the 
maximum loading was established at 0.1 mg AA139/mg PNPs and 0.140mg M33/mg 
PNPs. In case of AA139-PNPs based nanosystem, an increase from -22 mV (unloaded 
PNPs) to -18 mV (AA139-PNPs) was observed in the Z-potential. DLS measurements 
indicated a final hydrodynamic diameter of the NS of 100-130 nm. Regarding M33-PNP 
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nanosystem, Z-potential measurements showed an increase from -22 mV to -13 mV 
and a final hydrodynamic diameter of 125-250 nm after M33 peptide incorporation.  
With these results, previously radiolabelled AA139 and M33 were efficiently attached 
to PNPs. When the relative amount AMP/NP was set to 1/10, almost quantitative 
attachment of the peptides to the NP was observed. Radiochemical yields after 
purification close to 60% (referred to pure labelled peptide) could be achieved.  
Combination of AMPs and micelles 
Peptide based drugs are an important class of therapeutic agents but their 
development into commercial products is often hampered due to their inherent 
physico-chemical and biological instabilities. Issues such as aggregation, oxidative and 
hydrolytic degradation in vitro on one hand, and rapid proteolytic degradation and 
renal elimination in vivo on the other hand, impede their  development as therapeutic 
agents. In addition, poor permeability across biological membranes and degradation in 
the gastrointestinal tract significantly decrease the oral bioavailability of most peptide 
drugs and require parenteral administration (22, 23). This issue combined with their 
short biological half-lives requires frequent dosing that make peptide products less 
convenient for patients. All these pitfalls can be overcome by using phospholipid 
micelles as carriers. Phospholipids are an integral part of cell membrane and therefore 
when used in delivery systems, are considered safe and non-immunogenic. These lipids 
when conjugated with PEG become more soluble in water and when dispersed in 
aqueous media above a certain concentration form micelles. Unlike liposomes, 
micelles are self-assemblies of amphiphilic molecules that arrange themselves such 
that the hydrophobic parts of the molecule are clustered together and directed away 
from aqueous environment, while the hydrophilic domains are directed toward water. 
Phospholipid micelles such as those prepared using PEGylated lipids like DSPE-PEG2000 
(distearoyl-phosphatidylethanolamine chemically conjugated to PEG2000) are also 
called sterically stabilized micelles (SSM) and can be used as delivery systems for small 
molecule drugs (solubilized within the hydrophobic core of the micelles) or peptide 
drugs (postulated to reside in the PEG palisade of micelles). Several examples of 
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peptide drugs conjugated with sterically stabilized micelles can be found in the 
literature (24-33).      
In our work, we have used DSPE-PEG2000 to encapsulate the antimicrobial peptides, 
following the procedure provided by Utrecht University. According to their protocol, 
the maximum lipid concentration at which all the DSPE-PEG2000 lipids were solubilized 
in PBS buffer to form micelles was around 10-15 mM. At this lipid concentration, the 
maximum loading efficiency (99% ± 2) was achieved at a 7.7 mg/mL AA139 peptide 
concentration, resulting in a molar ratio of peptide: lipid = 1:5. In addition, stability 
studies indicated that above 95% of peptide was still encapsulated within micelles 
after one week of incubation at 4 °C. 
Employing the same molar ratio of radiolabelled peptide (both AA139 and M33): lipid 
(1:5), radiolabelled AMPs were successfully encapsulated within micelles. After 
purification of the crude of reaction by SEC, incorporation ratios were found to be 
higher than 95%.  
5.4.2. Animal Experiments 
5.4.2.1. In vivo imaging experiments of selected NCs: PNPs and its corresponding 
parent polymer 
In order to investigate the biological half-life of polymeric nanocarriers in the lungs, 
SPECT-CT images were acquired at different time points after administration to have a 
visual and intuitive idea about the residence time of each radiolabelled species within 
the lungs (Figure 5.7).  
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Figure 5.7. SPECT-CT axial images obtained after administration of 67Ga-Citrate (a), 
67Ga-Polymer (b), 67Ga-PNPs (c) by endotracheal insufflation at 0, 24 and 72 hours. 
 
Despite the regional distribution of the radioactivity was not completely homogenous, 
the presence of signal could be detected in almost the whole lungs at all times. The 
residence time of 67Ga-SCPNs and 67Ga-Polymer was evaluated and compared with 
67Ga-Citrate. As it can be seen in the images obtained at 72 hours after administration, 
only a small fraction of the administered citrate was still left within the lungs, whereas 
a significant fraction of PNPs and the corresponding linear polymer could still be 
detected in this organ. Since quantification of radioactivity with SPECT is not possible 
and images were only interpreted qualitatively, ex vivo studies were carried out to 
determine the amount of radioactivity that was still left at 3 and 6 days after 
administration (see below, section 5.4.2.3). 
5.4.2.2. In vivo imaging experiments of selected AMPs and NSs 
Similar to the previous study, PET-CT image sequences were obtained for all the 
studied AMPs and NSs (see Figure 5.8 for example of the biodistribution patterns of 
free [124I]AA139 peptide and [124I]NaI, used as control, at different time points).  
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Figure 5.8. PET-CT coronal images obtained at different time points after 
administration by endotracheal insufflation of [124I]AA139 (a) and [124I]NaI (b). PET 
images have been corregistered with CT images of the same animals for accurate 
location of the radioactive signal.   
 
In this particular example, just by visual inspection of the sequences, it was evident 
that the biodistribution patterns of the two species were different. The residence time 
of the peptide in the lungs seemed to be significantly higher than radioactive sodium 
iodide’s ([124I]NaI). Indeed, three hours after administration almost no signal was 
observed within the lungs when [124I]NaI was administered, whereas a significant 
fraction of peptide was still visible at the same time-point. The elimination pathways of 
these two species suggested excretion via urine and the gastrointestinal tract. 
Quantification results confirmed the trends observed in these in vivo sequences. The 
amount of radioactivity at each time point was fit to a mono-exponential decay 
equation and in this way half-lives of each compound were determined. As seen in 
Figure 5.9 (upper row), the residence time of AA139 (t1/2= 1.71 hours) was slightly 
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increased when coupled to polymeric NPs (t1/2= 2.08 hours). When the same peptide 
was encapsulated within a micelle, its biological half-life in the lungs increased 
significantly, up to 3 hours. 
Results obtained with M33 peptide (Figure 5.9, lower row) were quite similar. In this 
case, the half-life of the free peptide in the lungs was found to be slightly shorter than 
that obtained for AA139’s (t1/2= 1.08 hours). When M33 was attached to polymeric 
NPs, the radioactivity values obtained at different time points did not fit to a mono-
exponential decay equation (red line fitting) but to a bi-functional equation. Indeed, 
this was a two phase decay system where the half-life of the first phase was 1.12 hours 
(almost the same as for free M33’s) while values for the second phase were close to 13 
hours. These results suggest that not the whole amount of peptide was attached to the 
NPs, and a fraction of the peptide was “free” or loosely bound, behaving almost as the 
free peptide. Finally, when M33 was trapped within a micelle, its half-life was close to 
three hours. All half-life values are summarised in Figure 5.10.  
 
Figure 5.9. Decay curves for the different NSs, obtained from the in vivo quantification 
results. Half-life values are showed in red colour. 
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Figure 5.10. Summary of half-life values for all compounds, including [124I]NaI (control). 
For M33-PNP, the short and long half-lives are represented in blue and red colour, 
respectively.  
 
According to these results, both peptides were released from the polymeric 
nanocarriers relatively fast, suggesting that electrostatic interaction between the 
positively charged AMPs and PNPs (negatively charged) was not very stable in vivo. 
Similar dissociation of surface functionalizations attached via electrostatic interactions 
have been previously reported in the literature, for example in the case of gold 
nanoparticles (34) and superparamagnetic iron NPs (35, 36). Llop et al also studied the 
in vivo stability of protein coatings on poly(lacticco–glycolic) nanoparticles (PLGA-NPs) 
by nuclear imaging techniques (37).  NPs’ core and surrounding proteins were 
radiolabelled with two different gamma emitters and by energy discriminant single-
photon emission computerised tomography (SPECT) their biodistribution pattern was 
assessed. The displacement of the proteins or peptides from the NPs could be related 
with the formation of protein-coronas (38, 39). Actually, in physiological environment 
(blood, lymph, mucus, complete cell culture media and other biological fluids) a large 
amount and variety of proteins is present, which can interact with the administered 
NSs (AMP-NP) and form protein-coronas around the NPs.  
The results presented in this chapter were very useful to properly design the 
therapeutic-efficacy assays of these drugs carried out by project-partner Erasmus 
Medical Centre (Rotterdam, The Netherlands). By knowing the half-life of the drug at 
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different scenarios (free or attached to a NC) the dosing frequency to achieve the 
required amount of drug in the lungs could be determined.   
5.4.2.3. Ex vivo experiments of selected NCs: PNPs and the corresponding parent 
polymer 
When particles are administered by endotracheal insufflation, it is usually difficult to 
know the fraction that is deposited in the lungs with respect to the nebulised dose, 
especially in SPECT-CT experiments where absolute quantification is not possible. For 
this reason, ex vivo experiments of 67Ga-PNPs and 67Ga-Polymer immediately after 
administration were carried out. According to our results (using the Penn-Century 
MicroSprayer® Aerosolizer) 85±3% of the nebulised dose was deposited in the lungs 
independently of the nebulised compound. These results were used to correct the 
values obtained from the ex vivo studies of 67Ga-Citrate, 67Ga-PNPs and 67Ga-Polymer 
(n=3 per compound and labelled species).  
Ex vivo dissection and gamma counting results confirmed the trends observed in vivo. 
As it can be seen in Figure 5.11, >85% of the administered radioactivity was still in the 
lungs after 72 hours when labelled PNPs or the corresponding polymer were 
administered. On the contrary, almost 85% of the administered was cleared from the 
lungs at t=72 hours after administration of gallium citrate. Interestingly, at t=144 
hours, almost 40% of administered PNPs were cleared from the lungs whereas the 
amount of polymer within the lungs remained almost unchanged.  
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Figure 5.11 Percentage of administered radioactivity present in the lungs after 
endotracheal insufflation of 67Ga-citrate (black dots), 67Ga-labelled parent polymer 
(grey dots) and 67Ga-labelled PNPs (white dots). Results are expressed as mean ± 
standard deviation, n=3. 
 
These results confirm the long residence time of the PNPs as well as its corresponding 
parent polymer in the lungs. Moreover, they indicate that the way these polymers are 
organised has an effect on their release from the lungs. When polymers are collapsed 
forming in this way a NP, they are slowly washed out. On the contrary, when they are 
administered as polymers (not collapsed) they do not cross the lung membrane and 
remain in the lungs. 
No examples tackling the investigation of the residence time of PNPs after lung 
administration using molecular imaging techniques have been found in the literature. 
However, some previous works have investigated other NP types using other analytical 
techniques and eventually in vivo imaging. For example, Anderson et al. investigated 
the residence time of 2 different sized AgNPs (20 and 110 nm) delivered to rats by 
single nose-only aerosol exposure (40). Rat lung tissue was assessed at different time 
points for silver accumulations using inductively-coupled plasma mass spectrometry 
(ICP-MS), autometallography, and enhanced dark field microscopy. According to their 
results, 56 days post-exposure at least 33% of the initial delivered dose was still 
present for both AgNPs. Similarly, Woods et al also studied the biological fate of 
Albumin NPs in the lungs by a combination of SPECT-CT in vivo imaging experiments 
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and in vitro studies (41). Authors found out that 48 hours post administration, almost 
90% of radiolabelled albumin NPs remained in the lungs.  
5.5. Summary and Conclusion 
In this chapter, it has been demonstrated that nuclear imaging techniques are 
perfectly suited to investigate pharmacokinetic properties of drugs, drug carriers and 
their combination into nanosystems. Such determination has a definite incidence 
when defining the dosing regimen. The combination of nuclear imaging techniques 
reported here can be applied not only to the model systems assayed in the context of 
this PhD thesis, but to any novel nanomedicine as long as efficient radiolabelling 
strategies can be implemented. 
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Chapter 6. General conclusions 
1- The preparation of the radiofluorinated gases [18F]CF4 and [
18F]SF6 can be 
achieved following a simple method, based on a dual proton irradiation 
approach. This method results in higher production yields than direct proton 
irradiation of the fluorinated gases.     
2- The radiofluorinated gases [18F]CF4 and [
18F]SF6 are suitable tracers for the 
determination of regional lung ventilation using PET-CT, and may become 
powerful tools for the diagnostic, prognostic or evaluation of response to 
treatment in a wide variety of lung diseases. 
3- Endotracheal insufflations of aqueous solutions into rats using the PennCentury 
microsprayer result in close-to-quantitative deposition of the aerosol in the 
lungs, with non-uniform distribution within the different lung regions and high 
intra-subject variability.  
4- Lung administration of aerosols in rats using the commercially available 
Aeroneb nebuliser and the nebuliser developed by Ingeniatrics Tecnologías 
results in an homogeneous distribution of the aerosol within the lungs, 
although less than 0.1% of the nebulised solution is actually deposited in the 
lungs. 
5- Nuclear imaging techniques are perfectly suited to investigate the 
pharmacokinetic properties of drugs, drug carriers and their combinations into 
nanosystems. 
6- The residence time in the lungs of antimicrobial drugs after endotracheal 
insufflation can be prolonged by appropriate conjugation/entrapment 
with/into nanocarriers.  
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